##### Table of Contents

---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549



---



FORM 10-Q



---



(Mark One)

|x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|- | ---------------------------------------------------------------------------------------



For the quarterly period ended September 30, 2005



Or



| ̈ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|- | ----------------------------------------------------------------------------------------



Commission file number: 0-26190



---



US Oncology, Inc.

(Exact name of registrant as specified in its charter)



---



|                                                               |  |                                     
|-------------------------------------------------------------- |  | ------------------------------------
|Delaware                                                       |  | 84-1213501                          
|(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)



16825 Northchase
Drive, Suite 1300

Houston, Texas

77060

(Address of principal executive offices)

(Zip Code)



(832) 601-8766

(Registrants telephone number, including area code)



---



Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90
days.    Yes  x    No ̈



Indicate by check mark whether the Registrant (1) is an
accelerated filer (as defined in Rule 12(b)-2 of the Securities Exchange Act of 1934.)    Yes ̈No  x



Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12(b)-2 of the Securities Exchange Act of 1934.)    Yes ̈No  x



As of November 14, 2005, 100 shares of the Registrants common stock were outstanding.



---



---

##### Table of Contents

US ONCOLOGY, INC.

FORM 10-Q

SEPTEMBER 30, 2005



TABLE OF CONTENTS



|                              |  |                                                                                       |  |         
|----------------------------- |  | ------------------------------------------------------------------------------------- |  | --------
|                              |  |                                                                                       |  | PAGE NO.
|PART I.
FINANCIAL INFORMATION |  |                                                                                      
|                              |  |                                                                                      
|Item 1.                       |  | Condensed Consolidated Financial Statements:                                          |  |         
|                              |  | Condensed Consolidated Balance Sheet                                                  |  | 3       
|                              |  | Condensed Consolidated Statement of Operations and Comprehensive Income               |  | 4       
|                              |  | Condensed Consolidated Statement of Stockholders Equity                              |  | 6       
|                              |  | Condensed Consolidated Statement of Cash Flows                                        |  | 7       
|                              |  | Notes to Condensed Consolidated Financial Statements                                  |  | 9       
|                              |  |                                                                                      
|Item 2.                       |  | Managements Discussion and Analysis of Financial Condition and Results of Operations |  | 19      
|                              |  |                                                                                      
|Item 3.                       |  | Quantitative and Qualitative Disclosures about Market Risks                           |  | 36      
|                              |  |                                                                                      
|Item 4.                       |  | Controls and Procedures                                                               |  | 37      
|                              | 
|PART II.
OTHER INFORMATION    |  |                                                                                      
|                              |  |                                                                                      
|Item 1.                       |  | Legal Proceedings                                                                     |  | 38      
|                              |  |                                                                                      
|Item 4.                       |  | Submission of Matters to a Vote of Security Holders                                   |  | 38      
|                              |  |                                                                                      
|Item 6.                       |  | Exhibits                                                                              |  | 39      
|                              | 
|SIGNATURES                    |  | 41                                                                                   



-2-



---

##### Table of Contents

PART I. FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS



US ONCOLOGY, INC.

CONDENSED CONSOLIDATED BALANCE SHEET

(in thousands, except share information)

(unaudited)



|                                                                                                     |  |                   |           |   |                  |   |           |  
|---------------------------------------------------------------------------------------------------- |  | ----------------- | --------- | - | ---------------- | - | --------- | -
|                                                                                                     |  | September 30,2005 |           |   | December 31,2004 |  
|ASSETS                                                                                               |  |                   |           |   |                  |   |           |  
|Current assets:                                                                                      |  |                   |           |   |                  |   |           |  
|Cash and equivalents                                                                                 |  | $                 | 130,582   |   |                  | $ | 120,399   |  
|Accounts receivable                                                                                  |  |                   | 322,274   |   |                  |   | 308,561   |  
|Other receivables                                                                                    |  |                   | 140,518   |   |                  |   | 95,487    |  
|Prepaid expenses and other current assets                                                            |  |                   | 21,356    |   |                  |   | 16,556    |  
|Inventories                                                                                          |  |                   | 26,116    |   |                  |   | 5,080     |  
|Deferred income taxes                                                                                |  |                   | 4,865     |   |                  |   | 10,736    |  
|Due from affiliates                                                                                  |  |                   | 48,453    |   |                  |   | 53,865    |  
|                                                                                                     |  |                   |           |   |                  |   |           |  
|Total current assets                                                                                 |  |                   | 694,164   |   |                  |   | 610,684   |  
|Property and equipment, net                                                                          |  |                   | 399,795   |   |                  |   | 383,141   |  
|Service agreements, net                                                                              |  |                   | 245,873   |   |                  |   | 255,680   |  
|Goodwill                                                                                             |  |                   | 716,732   |   |                  |   | 730,278   |  
|Other assets                                                                                         |  |                   | 50,216    |   |                  |   | 52,015    |  
|                                                                                                     |  |                   |           |   |                  |   |           |  
|                                                                                                     |  | $                 | 2,106,780 |   |                  | $ | 2,031,798 |  
|                                                                                                     |  |                   |           |   |                  |   |           |  
|LIABILITIES AND STOCKHOLDERS EQUITY                                                                 |  |                   |           |   |                  |   |           |  
|Current liabilities:                                                                                 |  |                   |           |   |                  |   |           |  
|Current maturities of long-term indebtedness                                                         |  | $                 | 10,399    |   |                  | $ | 10,063    |  
|Accounts payable                                                                                     |  |                   | 276,946   |   |                  |   | 181,136   |  
|Due to affiliates                                                                                    |  |                   | 119,870   |   |                  |   | 112,221   |  
|Accrued compensation cost                                                                            |  |                   | 25,573    |   |                  |   | 31,322    |  
|Accrued interest payable                                                                             |  |                   | 10,747    |   |                  |   | 25,315    |  
|Income taxes payable                                                                                 |  |                   | 2,278     |   |                  |   | 23,297    |  
|Other accrued liabilities                                                                            |  |                   | 38,378    |   |                  |   | 40,753    |  
|                                                                                                     |  |                   |           |   |                  |   |           |  
|Total current liabilities                                                                            |  |                   | 484,191   |   |                  |   | 424,107   |  
|                                                                                                     |  |                  
|Deferred revenue                                                                                     |  |                   | 6,904     |   |                  |   | 6,692     |  
|Deferred income taxes                                                                                |  |                   | 33,727    |   |                  |   | 28,980    |  
|Long-term indebtedness                                                                               |  |                   | 969,809   |   |                  |   | 978,937   |  
|Other long-term liabilities                                                                          |  |                   | 8,335     |   |                  |   | 176       |  
|                                                                                                     |  |                   |           |   |                  |   |           |  
|Total liabilities                                                                                    |  |                   | 1,502,966 |   |                  |   | 1,438,892 |  
|Minority interest                                                                                    |  |                   | 12,704    |   |                  |   | 10,583    |  
|Stockholders equity:                                                                                |  |                   |           |   |                  |   |           |  
|Common stock, $.01 par value, 100 shares authorized, 100 shares issued and outstanding, respectively |  |                   | 1         |   |                  |   | 1         |  
|Additional paid-in capital                                                                           |  |                   | 583,684   |   |                  |   | 567,364   |  
|Deferred compensation                                                                                |  |                   | (4,352    | ) |                  |   | (6,794    | )
|Retained earnings                                                                                    |  |                   | 11,777    |   |                  |   | 21,752    |  
|                                                                                                     |  |                   |           |   |                  |   |           |  
|Total stockholders equity                                                                           |  |                   | 591,110   |   |                  |   | 582,323   |  
|                                                                                                     |  |                   |           |   |                  |   |           |  
|                                                                                                     |  | $                 | 2,106,780 |   |                  | $ | 2,031,798 |  
|                                                                                                     |  |                   |           |   |                  |   |           |  



The accompanying notes
are an integral part of this statement.



-3-



---

##### Table of Contents

US ONCOLOGY, INC.

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE INCOME

(in thousands)

(unaudited)



|                                                  |  |                                    |         |   |                                               |   |         |                                                    |  |   |         |  
|------------------------------------------------- |  | ---------------------------------- | ------- | - | --------------------------------------------- | - | ------- | -------------------------------------------------- |  | - | ------- | -
|                                                  |  | Three MonthsEndedSeptember 30,2005 |         |   | Period fromJuly 1, 2004throughAugust 20, 2004 |   |         | Period fromAugust 21, 2004throughSeptember 30,2004 | 
|                                                  |  | (Successor)                        |         |   | (Predecessor)                                 |   |         | (Successor)                                        | 
|Product revenues                                  |  | $                                  | 418,724 |   |                                               | $ | 213,687 |                                                    |  | $ | 149,271 |  
|Service revenues                                  |  |                                    | 229,621 |   |                                               |   | 121,928 |                                                    |  |   | 103,845 |  
|                                                  |  |                                    |         |   |                                               |   |         |                                                    |  |   |         |  
|Total revenues                                    |  |                                    | 648,345 |   |                                               |   | 335,615 |                                                    |  |   | 253,116 |  
|                                                  |  |                                    |         |   |                                               |   |         |                                                    |  |   |         |  
|Cost of products                                  |  |                                    | 400,876 |   |                                               |   | 200,225 |                                                    |  |   | 144,764 |  
|                                                  |  |                                    |        
|Cost of services:                                 |  |                                    |         |   |                                               |   |         |                                                    |  |   |         |  
|Operating compensation and benefits               |  |                                    | 107,138 |   |                                               |   | 55,015  |                                                    |  |   | 42,928  |  
|Other operating costs                             |  |                                    | 63,069  |   |                                               |   | 32,183  |                                                    |  |   | 25,450  |  
|Depreciation and amortization                     |  |                                    | 17,159  |   |                                               |   | 8,418   |                                                    |  |   | 6,436   |  
|                                                  |  |                                    |         |   |                                               |   |         |                                                    |  |   |         |  
|Total cost of services                            |  |                                    | 187,366 |   |                                               |   | 95,616  |                                                    |  |   | 74,814  |  
|                                                  |  |                                    |         |   |                                               |   |         |                                                    |  |   |         |  
|Total cost of products and services               |  |                                    | 588,242 |   |                                               |   | 295,841 |                                                    |  |   | 219,578 |  
|                                                  |  |                                    |        
|General and administrative expense                |  |                                    | 18,267  |   |                                               |   | 11,376  |                                                    |  |   | 7,482   |  
|Merger-related charges                            |  |                                    |        |   |                                               |   | 9,625   |                                                    |  |   | 6,425   |  
|Depreciation and amortization                     |  |                                    | 3,783   |   |                                               |   | 2,865   |                                                    |  |   | 2,483   |  
|                                                  |  |                                    |         |   |                                               |   |         |                                                    |  |   |         |  
|Total costs and expenses                          |  |                                    | 610,292 |   |                                               |   | 319,707 |                                                    |  |   | 235,968 |  
|                                                  |  |                                    |         |   |                                               |   |         |                                                    |  |   |         |  
|Income from operations                            |  |                                    | 38,053  |   |                                               |   | 15,908  |                                                    |  |   | 17,148  |  
|                                                  |  |                                    |        
|Other income (expense):                           |  |                                    |         |   |                                               |   |         |                                                    |  |   |         |  
|Interest expense, net                             |  |                                    | (20,833 | ) |                                               |   | (2,008  | )                                                  |  |   | (9,069  | )
|Loss on early extinguishment of debt              |  |                                    |        |   |                                               |   | (38,272 | )                                                  |  |   |        |  
|                                                  |  |                                    |         |   |                                               |   |         |                                                    |  |   |         |  
|Income (loss) before income taxes                 |  |                                    | 17,220  |   |                                               |   | (24,372 | )                                                  |  |   | 8,079   |  
|Income tax (provision) benefit                    |  |                                    | (6,657  | ) |                                               |   | 6,023   |                                                    |  |   | (3,346  | )
|                                                  |  |                                    |         |   |                                               |   |         |                                                    |  |   |         |  
|Net income (loss) and comprehensive income (loss) |  | $                                  | 10,563  |   |                                               | $ | (18,349 | )                                                  |  | $ | 4,733   |  
|                                                  |  |                                    |         |   |                                               |   |         |                                                    |  |   |         |  



The accompanying notes
are an integral part of this statement.



-4-



---

##### Table of Contents

US ONCOLOGY, INC.

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE INCOME

(in thousands)

(unaudited)



|                                                    |  |                                   |           |   |                                                  |   |           |                                                    |  |   |         |  
|--------------------------------------------------- |  | --------------------------------- | --------- | - | ------------------------------------------------ | - | --------- | -------------------------------------------------- |  | - | ------- | -
|                                                    |  | Nine MonthsEndedSeptember 30,2005 |           |   | Period fromJanuary 1, 2004throughAugust 20, 2004 |   |           | Period fromAugust 21, 2004throughSeptember 30,2004 | 
|                                                    |  | (Successor)                       |           |   | (Predecessor)                                    |   |           | (Successor)                                        | 
|Product revenues                                    |  | $                                 | 1,181,431 |   |                                                  | $ | 901,616   |                                                    |  | $ | 149,271 |  
|Service revenues                                    |  |                                   | 672,179   |   |                                                  |   | 524,238   |                                                    |  |   | 103,845 |  
|                                                    |  |                                   |           |   |                                                  |   |           |                                                    |  |   |         |  
|Total revenues                                      |  |                                   | 1,853,610 |   |                                                  |   | 1,425,854 |                                                    |  |   | 253,116 |  
|                                                    |  |                                   |           |   |                                                  |   |           |                                                    |  |   |         |  
|Cost of products                                    |  |                                   | 1,129,637 |   |                                                  |   | 839,774   |                                                    |  |   | 144,764 |  
|                                                    |  |                                   |          
|Cost of services:                                   |  |                                   |           |   |                                                  |   |           |                                                    |  |   |         |  
|Operating compensation and benefits                 |  |                                   | 310,447   |   |                                                  |   | 244,168   |                                                    |  |   | 42,928  |  
|Other operating costs                               |  |                                   | 183,117   |   |                                                  |   | 144,200   |                                                    |  |   | 25,450  |  
|Depreciation and amortization                       |  |                                   | 50,027    |   |                                                  |   | 37,375    |                                                    |  |   | 6,436   |  
|                                                    |  |                                   |           |   |                                                  |   |           |                                                    |  |   |         |  
|Total cost of services                              |  |                                   | 543,591   |   |                                                  |   | 425,743   |                                                    |  |   | 74,814  |  
|                                                    |  |                                   |           |   |                                                  |   |           |                                                    |  |   |         |  
|Total cost of products and services                 |  |                                   | 1,673,228 |   |                                                  |   | 1,265,517 |                                                    |  |   | 219,578 |  
|                                                    |  |                                   |          
|General and administrative expense                  |  |                                   | 52,879    |   |                                                  |   | 40,676    |                                                    |  |   | 7,482   |  
|Compensation expense under long-term incentive plan |  |                                   | 14,507    |   |                                                  |   |          |                                                    |  |   |        |  
|Merger-related charges                              |  |                                   |          |   |                                                  |   | 9,625     |                                                    |  |   | 6,425   |  
|Depreciation and amortization                       |  |                                   | 13,105    |   |                                                  |   | 13,198    |                                                    |  |   | 2,483   |  
|                                                    |  |                                   |           |   |                                                  |   |           |                                                    |  |   |         |  
|Total costs and expenses                            |  |                                   | 1,753,719 |   |                                                  |   | 1,329,016 |                                                    |  |   | 235,968 |  
|                                                    |  |                                   |           |   |                                                  |   |           |                                                    |  |   |         |  
|Income from operations                              |  |                                   | 99,891    |   |                                                  |   | 96,838    |                                                    |  |   | 17,148  |  
|                                                    |  |                                   |          
|Other income (expense):                             |  |                                   |           |   |                                                  |   |           |                                                    |  |   |         |  
|Interest expense, net                               |  |                                   | (62,166   | ) |                                                  |   | (10,931   | )                                                  |  |   | (9,069  | )
|Loss on early extinguishment of debt                |  |                                   |          |   |                                                  |   | (38,272   | )                                                  |  |   |        |  
|Other income                                        |  |                                   |          |   |                                                  |   | 622       |                                                    |  |   |        |  
|                                                    |  |                                   |           |   |                                                  |   |           |                                                    |  |   |         |  
|Income before income taxes                          |  |                                   | 37,725    |   |                                                  |   | 48,257    |                                                    |  |   | 8,079   |  
|Income tax provision                                |  |                                   | (14,976   | ) |                                                  |   | (21,939   | )                                                  |  |   | (3,346  | )
|                                                    |  |                                   |           |   |                                                  |   |           |                                                    |  |   |         |  
|Net income and comprehensive income                 |  | $                                 | 22,749    |   |                                                  | $ | 26,318    |                                                    |  | $ | 4,733   |  
|                                                    |  |                                   |           |   |                                                  |   |           |                                                    |  |   |         |  



The accompanying notes
are an integral part of this statement.



-5-



---

##### Table of Contents

US ONCOLOGY, INC.

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS EQUITY

(in thousands, except share information)

(unaudited)



|                                                                |  |               |  |          |   |                           |   |                      |  |   |                   |   |  |       |         |   |  |   |         |  
|--------------------------------------------------------------- |  | ------------- |  | -------- | - | ------------------------- | - | -------------------- |  | - | ----------------- | - |  | ----- | ------- | - |  | - | ------- | -
|                                                                |  | Shares Issued |  | ParValue |   | AdditionalPaid-In Capital |   | DeferredCompensation |  |   | Retained Earnings |   |  | Total |        
|                                                                |  |               |  |          |   |                          
|Balance at December 31, 2004                                    |  | 100           |  | $        | 1 |                           | $ | 567,364              |  | $ | (6,794            | ) |  | $     | 21,752  |   |  | $ | 582,323 |  
|Contribution of private equity offering proceeds                |  |              |  |          |  |                           |   | 899                  |  |   |                  |   |  |       |        |   |  |   | 899     |  
|Contribution of expenses associated with Holdings debt offering |  |              |  |          |  |                           |   | 15,001               |  |   |                  |   |  |       |        |   |  |   | 15,001  |  
|Contribution of restricted stock award issuances                |  |              |  |          |  |                           |   | 420                  |  |   | (420              | ) |  |       |        |   |  |   |        |  
|Amortization of deferred compensation expense                   |  |              |  |          |  |                           |   |                     |  |   | 2,862             |   |  |       |        |   |  |   | 2,862   |  
|Dividend declared                                               |  |              |  |          |  |                           |   |                     |  |   |                  |   |  |       | (32,724 | ) |  |   | (32,724 | )
|Net income                                                      |  |              |  |          |  |                           |   |                     |  |   |                  |   |  |       | 22,749  |   |  |   | 22,749  |  
|                                                                |  |               |  |          |   |                           |   |                      |  |   |                   |   |  |       |         |   |  |   |         |  
|Balance at September 30, 2005                                   |  | 100           |  | $        | 1 |                           | $ | 583,684              |  | $ | (4,352            | ) |  | $     | 11,777  |   |  | $ | 591,110 |  
|                                                                |  |               |  |          |   |                           |   |                      |  |   |                   |   |  |       |         |   |  |   |         |  



The accompanying notes
are an integral part of this statement.



-6-



---

##### Table of Contents

US ONCOLOGY, INC.

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

(in thousands)

(unaudited)



|                                                                                  |  |                                   |         |   |                                                  |   |         |                                                    |  |   |         |  
|--------------------------------------------------------------------------------- |  | --------------------------------- | ------- | - | ------------------------------------------------ | - | ------- | -------------------------------------------------- |  | - | ------- | -
|                                                                                  |  | Nine MonthsEndedSeptember 30,2005 |         |   | Period fromJanuary 1, 2004throughAugust 20, 2004 |   |         | Period fromAugust 21, 2004throughSeptember 30,2004 | 
|                                                                                  |  | (Successor)                       |         |   | (Predecessor)                                    |   |         | (Successor)                                        | 
|Cash flows from operating activities:                                             |  |                                   |         |   |                                                  |   |         |                                                    |  |   |         |  
|                                                                                  |  |                                   |        
|Net income                                                                        |  | $                                 | 22,749  |   |                                                  | $ | 26,318  |                                                    |  | $ | 4,733   |  
|                                                                                  |  |                                   |        
|Adjustments to reconcile net income to net cash provided by operating activities: |  |                                   |         |   |                                                  |   |         |                                                    |  |   |         |  
|Depreciation and amortization                                                     |  |                                   | 63,132  |   |                                                  |   | 50,573  |                                                    |  |   | 8,919   |  
|Deferred revenue                                                                  |  |                                   | 212     |   |                                                  |   |        |                                                    |  |   |        |  
|Deferred income taxes                                                             |  |                                   | 14,976  |   |                                                  |   | 7,371   |                                                    |  |   | 5,556   |  
|Non-cash compensation expense                                                     |  |                                   | 2,862   |   |                                                  |   | 65      |                                                    |  |   | 921     |  
|Non-cash items                                                                    |  |                                   |        |   |                                                  |   | (105    | )                                                  |  |   |        |  
|Undistributed (earnings) losses in joint ventures                                 |  |                                   | 1,047   |   |                                                  |   | (20     | )                                                  |  |   | 90      |  
|Loss on early extinguishment of debt                                              |  |                                   |        |   |                                                  |   | 38,272  |                                                    |  |   |        |  
|(Increase) Decrease in:                                                           |  |                                   |         |   |                                                  |   |         |                                                    |  |   |         |  
|Accounts receivable                                                               |  |                                   | (34,733 | ) |                                                  |   | (39,151 | )                                                  |  |   | 25,035  |  
|Prepaid expenses and other current assets                                         |  |                                   | (31,163 | ) |                                                  |   | (28,352 | )                                                  |  |   | (8,629  | )
|Inventories                                                                       |  |                                   | (21,036 | ) |                                                  |   | (5,721  | )                                                  |  |   | (21,755 | )
|Other assets                                                                      |  |                                   | 3,467   |   |                                                  |   | (396    | )                                                  |  |   | 1,735   |  
|Increase (Decrease) in:                                                           |  |                                   |         |   |                                                  |   |         |                                                    |  |   |         |  
|Accounts payable                                                                  |  |                                   | 95,810  |   |                                                  |   | 35,525  |                                                    |  |   | 41,480  |  
|Due from/to affiliates                                                            |  |                                   | 13,127  |   |                                                  |   | 23,578  |                                                    |  |   | 23,669  |  
|Income taxes receivable/payable                                                   |  |                                   | (7,640  | ) |                                                  |   | 14,003  |                                                    |  |   | (25,931 | )
|Other accrued liabilities                                                         |  |                                   | (22,622 | ) |                                                  |   | 9,689   |                                                    |  |   | 3,503   |  
|                                                                                  |  |                                   |         |   |                                                  |   |         |                                                    |  |   |         |  
|Net cash provided by operating activities                                         |  |                                   | 100,188 |   |                                                  |   | 131,649 |                                                    |  |   | 59,326  |  
|                                                                                  |  |                                   |         |   |                                                  |   |         |                                                    |  |   |         |  
|Cash flows from investing activities:                                             |  |                                   |         |   |                                                  |   |         |                                                    |  |   |         |  
|Acquisition of property and equipment                                             |  |                                   | (62,762 | ) |                                                  |   | (50,339 | )                                                  |  |   | (7,205  | )
|Payments in affiliation transactions                                              |  |                                   | (4,515  | ) |                                                  |   |        |                                                    |  |   |        |  
|Proceeds from contract separation                                                 |  |                                   | 1,807   |   |                                                  |   |        |                                                    |  |   |        |  
|Proceeds from sale of real estate interests in joint venture                      |  |                                   | 900     |   |                                                  |   |        |                                                    |  |   |        |  
|                                                                                  |  |                                   |         |   |                                                  |   |         |                                                    |  |   |         |  
|Net cash used in investing activities                                             |  | $                                 | (64,570 | ) |                                                  | $ | (50,339 | )                                                  |  | $ | (7,205  | )
|                                                                                  |  |                                   |         |   |                                                  |   |         |                                                    |  |   |         |  



(Continued on following
page)



The accompanying notes are an integral part of this
statement.



-7-



---

##### Table of Contents

US ONCOLOGY, INC.

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

(in thousands)

(unaudited)



|                                                                |  |                                   |         |   |                                                  |   |         |                                                    |  |   |            |  
|--------------------------------------------------------------- |  | --------------------------------- | ------- | - | ------------------------------------------------ | - | ------- | -------------------------------------------------- |  | - | ---------- | -
|                                                                |  | Nine MonthsEndedSeptember 30,2005 |         |   | Period fromJanuary 1, 2004throughAugust 20, 2004 |   |         | Period fromAugust 21, 2004throughSeptember 30,2004 | 
|                                                                |  | (Successor)                       |         |   | (Predecessor)                                    |   |         | (Successor)                                        | 
|Cash flows from financing activities:                           |  |                                   |         |   |                                                  |   |         |                                                    |  |   |            |  
|Equity investment by parent                                     |  | $                                 |        |   |                                                  | $ |        |                                                    |  | $ | 309,100    |  
|Proceeds from other indebtedness                                |  |                                   | 13,245  |   |                                                  |   |        |                                                    |  |   |           |  
|Proceeds from credit facility                                   |  |                                   |        |   |                                                  |   |        |                                                    |  |   | 400,000    |  
|Proceeds from senior subordinated notes                         |  |                                   |        |   |                                                  |   |        |                                                    |  |   | 575,000    |  
|Repayment of term loan                                          |  |                                   | (16,912 | ) |                                                  |   |        |                                                    |  |   |           |  
|Repayment of credit facility                                    |  |                                   |        |   |                                                  |   |        |                                                    |  |   | (67,277    | )
|Repayment of senior subordinated notes                          |  |                                   |        |   |                                                  |   |        |                                                    |  |   | (172,000   | )
|Repayment of other indebtedness                                 |  |                                   | (4,944  | ) |                                                  |   | (10,336 | )                                                  |  |   | (4,951     | )
|Net distributions to parent                                     |  |                                   | (16,824 | ) |                                                  |   |        |                                                    |  |   |           |  
|Debt issuance costs                                             |  |                                   |        |   |                                                  |   |        |                                                    |  |   | (50,045    | )
|Net payments in lieu of stock issuance upon contract Separation |  |                                   |        |   |                                                  |   |        |                                                    |  |   | (12,033    | )
|Purchase of common stock and outstanding options                |  |                                   |        |   |                                                  |   |        |                                                    |  |   | (1,172,956 | )
|Proceeds from exercise of options                               |  |                                   |        |   |                                                  |   | 18,726  |                                                    |  |   |           |  
|Purchase of treasury stock                                      |  |                                   |        |   |                                                  |   | (4,247  | )                                                  |  |   |           |  
|                                                                |  |                                   |         |   |                                                  |   |         |                                                    |  |   |            |  
|Net cash provided by (used in) financing activities             |  |                                   | (25,435 | ) |                                                  |   | 4,143   |                                                    |  |   | (195,162   | )
|                                                                |  |                                   |         |   |                                                  |   |         |                                                    |  |   |            |  
|Increase (Decrease) in cash and equivalents                     |  |                                   | 10,183  |   |                                                  |   | 85,453  |                                                    |  |   | (143,041   | )
|Cash and equivalents:                                           |  |                                   |         |   |                                                  |   |         |                                                    |  |   |            |  
|Beginning of period                                             |  |                                   | 120,399 |   |                                                  |   | 124,514 |                                                    |  |   | 209,967    |  
|                                                                |  |                                   |         |   |                                                  |   |         |                                                    |  |   |            |  
|End of period                                                   |  | $                                 | 130,582 |   |                                                  | $ | 209,967 |                                                    |  | $ | 66,926     |  
|                                                                |  |                                   |         |   |                                                  |   |         |                                                    |  |   |            |  
|Supplemental Cash Flow Information:                             |  |                                   |         |   |                                                  |   |         |                                                    |  |   |            |  
|Interest paid                                                   |  | $                                 | 73,066  |   |                                                  | $ | 19,303  |                                                    |  | $ | 75         |  
|Taxes paid (refunded)                                           |  |                                   | 150     |   |                                                  |   | 667     |                                                    |  |   | (9,139     | )
|Delivery of common stock in affiliation transactions            |  |                                   |        |   |                                                  |   | 1,278   |                                                    |  |   |           |  



The accompanying notes
are an integral part of this statement.



-8-



---

##### Table of Contents

US ONCOLOGY, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

QUARTER ENDED SEPTEMBER 30, 2005



NOTE 1  BASIS OF PRESENTATION



The accompanying unaudited condensed consolidated financial statements of US Oncology, Inc. (US Oncology or the
Company) have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) for interim financial reporting and in accordance with Form 10-Q and Rule 10.01 of Regulation S-X. Accordingly,
they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the unaudited condensed consolidated financial statements contained in
this report reflect all adjustments that are normal and recurring in nature and considered necessary for a fair presentation of the financial position and the results of operations for the interim periods presented. The results of operations for the
interim period are not necessarily indicative of the results expected for the full year. The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that
affect the reported amounts of assets, liabilities, revenues and expenses, as well as disclosures of contingent assets and liabilities. Because of inherent uncertainties in this process, actual future results could differ from those expected at the
reporting date. These unaudited condensed consolidated financial statements, footnote disclosures and other information should be read in conjunction with the financial statements and the notes thereto included in Amendment No. 2 to the
Companys Registration Statement on Form S-4, filed with the SEC on March 16, 2005, and subsequent filings.



Certain previously reported financial information has been reclassified to conform to the interim presentation.



NOTE 2  THE MERGER TRANSACTION



On August 20, 2004, Oiler Acquisition Corp., a wholly-owned
subsidiary of US Oncology Holdings, Inc. (Holdings) merged with and into US Oncology, with US Oncology continuing as the surviving corporation and as a wholly-owned subsidiary of Holdings. The merger transaction was valued at
approximately $1.6 billion. The merger and related transactions are referred to in this report as the Merger or August Transactions.



Prior to the merger, 14,307,501 shares of US Oncology common stock then owned by Welsh, Carson, Anderson & Stowe IX, L.P.
(WCAS) and its affiliates, with a fair value of $215.3 million, were contributed to Holdings in exchange for shares of Holdings common and participating preferred stock. Upon consummation of the merger, these common shares
were cancelled without payment of any merger consideration. The Company repaid approximately $281.1 million of existing indebtedness and incurred approximately $104.4 million in fees and expenses in connection with the August Transactions.



The August Transactions were financed by:



| |  |  | a cash common and preferred equity investment in Holdings by WCAS and its related equity investors of $302.4 million, which funds were contributed to US Oncology;
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the borrowing by US Oncology of $400.0 million in term loans under its new senior secured credit facility;
| | - |  | ----------------------------------------------------------------------------------------------------------



| |  |  | $245.0 million of cash on hand at the closing date; and
| | - |  | -------------------------------------------------------



| |  |  | the issuance by US Oncology of $300.0 million aggregate principal amount of senior notes and $275.0 million aggregate principal amount of senior subordinated notes.
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------



The August Transactions were accounted for under the purchase
method of accounting prescribed in Statement of Financial Accounting Standards (SFAS) No. 141, Business Combination, (SFAS No. 141), with intangible assets recorded in accordance with SFAS No. 142,
Goodwill and Other Intangible Assets (SFAS No. 142). The purchase price, including transaction-related fees, was allocated to the Companys tangible and identifiable intangible assets and liabilities based upon estimates of
fair value, with the remainder allocated to goodwill.



Subsequent to the
initial capitalization of the Company, additional capital contributions of $39.8 million were received from Holdings. The contributions represent the proceeds from private equity offerings to certain affiliated physicians and employees of the
Company and to certain members of management.



-9-



---

##### Table of Contents

US ONCOLOGY, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

QUARTER ENDED SEPTEMBER 30, 2005
continued



NOTE 3  REVENUES



The Company derives revenues primarily from (i) comprehensive service arrangements with
physician practices; (ii) pharmaceutical services agreements with physician practices under the service line model; (iii) research agreements with pharmaceutical manufacturers and other trial sponsors and (iv) fees paid by
pharmaceutical companies for services as a group purchasing organization, data services and other services.



Governmental programs, such as Medicare and Medicaid, are collectively the affiliated practices largest payors. For the three months ended September 30, 2005 and for the periods from July 1, 2004
through August 20, 2004 (predecessor) combined with August 21, 2004 through September 30, 2004 (successor), the affiliated practices derived 38.0% and 42.1%, respectively, of their net patient revenue from services provided under the
Medicare program (of which 2.2% and 3.5%, respectively, relates to Medicare managed care programs) and 2.9% and 2.6%, respectively, from services provided under state Medicaid programs. For the nine months ended September 30, 2005 and for the
periods from January 1, 2004 through August 20, 2004 (predecessor) combined with August 21, 2004 through September 30, 2004 (successor), the affiliated practices derived 39.0% and 41.5%, respectively, of their net patient revenue
from services provided under the Medicare program (of which 2.1% and 3.5%, respectively, relates to Medicare managed care programs) and 2.8% and 2.5%, respectively, from services provided under state Medicaid programs. For the nine months ended
September 30, 2005 and for the periods from January 1, 2004 through August 20, 2004 (predecessor) combined with August 21, 2004 through September 30, 2004 (successor), capitation revenues were less than 1% of total net
patient revenue. Changes in the payor reimbursement rates, particularly Medicare and Medicaid, or in affiliated practices payor mix could materially and adversely affect the Companys revenues.



Effective January 1, 2005, Medicare changed the method by which it reimburses providers
for oncology pharmaceuticals administered in physicians offices, including those in the US Oncology network. Medicare now pays oncologists the average sales price (ASP) for drugs plus 6%. Previously, Medicare reimbursed physicians
for oncology pharmaceuticals based on average wholesale price (AWP), which is significantly higher than ASP. Conversion to ASP-based reimbursement from AWP reduced Medicare reimbursement for pharmaceuticals approximately 15%, effective
January 1, 2005. Also, since implementation, ASP has not remained constant. During the nine months ended September 30, 2005, the Company experienced a decline of approximately 7% in Medicare reimbursement since January 1, 2005.
Because a significant majority of US Oncologys service revenues and margins is based upon the revenues and margins of our affiliated practices, this change negatively affected US Oncologys financial performance.



The Companys most significant, and only service agreement to provide more than 10% of
total revenues, is with Texas Oncology, P.A. which accounted for approximately 25% of total revenues for the nine months ended September 30, 2005, and for the periods from January 1, 2004 through August 20, 2004 (predecessor) combined
with August 21, 2004 through September 30, 2004 (successor), respectively.



NOTE 4  INTANGIBLE ASSETS AND GOODWILL



Changes in intangible assets relating to service agreements and goodwill during the nine months ended September 30, 2005 consisted of the following (in thousands):



|                                        |  |                        |         |   |          |   |         |  
|--------------------------------------- |  | ---------------------- | ------- | - | -------- | - | ------- | -
|                                        |  | ServiceAgreements, net |         |   | Goodwill |  
|Balance at December 31, 2004            |  | $                      | 255,680 |   |          | $ | 730,278 |  
|Adjustments for new basis               |  |                        |        |   |          |   | (13,546 | )
|Practice affiliations                   |  |                        | 3,100   |   |          |   |        |  
|Practice disaffiliations and other, net |  |                        | (1,592  | ) |          |   |        |  
|Amortization expense                    |  |                        | (11,315 | ) |          |   |        |  
|                                        |  |                        |         |   |          |   |         |  
|Balance at September 30, 2005           |  | $                      | 245,873 |   |          | $ | 716,732 |  
|                                        |  |                        |         |   |          |   |         |  



-10-



---

##### Table of Contents

US ONCOLOGY, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

QUARTER ENDED SEPTEMBER 30, 2005
continued



The fair values of the identifiable intangibles acquired and the
amount of goodwill recorded as a result of the August Transactions were determined based on an independent third-party valuation. The allocation of the purchase price was completed during the quarter ended September 30, 2005. Adjustments to
goodwill during the nine months ended September 30, 2005 relate to changes to the preliminary purchase price allocation for the August Transactions to reflect the final valuation of acquired assets and assumed liabilities.



Accumulated amortization relating to service agreements was $10.8 million and $4.1
million at September 30, 2005 and December 31, 2004, respectively.



The carrying value of goodwill is subject to impairment tests under the requirements of SFAS No. 142. Goodwill was allocated to each of the Companys reporting units based on their fair values at the date of the August
Transactions. The Company performs impairment tests on an ongoing basis annually, and more frequently in the event of any impairment indicators. No impairments were recorded during the nine months ended September 30, 2005.



NOTE 5  INDEBTEDNESS



As of September 30, 2005 and December 31, 2004, long-term indebtedness consisted
of the following (in thousands):



|                                              |  |                    |         |   |                   |   |         |  
|--------------------------------------------- |  | ------------------ | ------- | - | ----------------- | - | ------- | -
|                                              |  | September 30, 2005 |         |   | December 31, 2004 |  
|Term loan                                     |  | $                  | 381,088 |   |                   | $ | 398,000 |  
|9.0% Senior Notes, due 2012                   |  |                    | 300,000 |   |                   |   | 300,000 |  
|10.75% Senior Subordinated Notes, due 2014    |  |                    | 275,000 |   |                   |   | 275,000 |  
|9.625% Senior Subordinated Notes, due 2012    |  |                    | 3,000   |   |                   |   | 3,000   |  
|Subordinated notes                            |  |                    | 8,168   |   |                   |   | 12,889  |  
|Mortgage, capital lease obligations and other |  |                    | 12,952  |   |                   |   | 111     |  
|                                              |  |                    |         |   |                   |   |         |  
|                                              |  |                    | 980,208 |   |                   |   | 989,000 |  
|Less: Current maturities                      |  |                    | (10,399 | ) |                   |   | (10,063 | )
|                                              |  |                    |         |   |                   |   |         |  
|                                              |  | $                  | 969,809 |   |                   | $ | 978,937 |  
|                                              |  |                    |         |   |                   |   |         |  



Senior Secured Credit Facility



The senior secured credit facility provides for senior secured financing
of up to $560.0 million, consisting of:



| |  | a $160.0 million revolving credit facility, none of which was drawn as of September 30, 2005, including both a letter of credit sub-facility and a swingline loan sub-facility,
that will terminate in six years, and
|- |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  | a $400.0 million term loan facility with a maturity of seven years that was drawn in full in connection with the consummation of the August Transactions. The amount outstanding
under the term loan was $381.1 million as of September 30, 2005.
|- |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



The interest rates applicable to loans, other than swingline loans, under the senior secured credit facility are, at the Companys option, equal to either an alternate base rate or an adjusted LIBOR for a one, two, three or six month
interest period chosen by the Company (or a nine or 12 month period if all lenders agree to make an interest period of such duration available) in each case, plus an applicable margin percentage. Swingline loans bear interest at the interest
rate applicable to alternate base rate revolving loans.



The alternate base
rate is the greater of (1) the prime rate or (2) one-half of 1% over the weighted average of the rates on overnight Federal funds transactions as published by the Federal Reserve Bank of New York. The adjusted



-11-



---

##### Table of Contents

US ONCOLOGY, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

QUARTER ENDED SEPTEMBER 30, 2005
continued



LIBOR is based upon settlement rates in the London interbank
market. Currently, the applicable margin percentage is a percentage per annum equal to (1) 1.75% for alternate base rate term loans, (2) 2.75% for adjusted LIBOR term loans, (3) 1.50% for alternate base rate revolving loans and
(4) 2.50% for adjusted LIBOR revolving loans.



Indebtedness under the
senior secured credit facility is guaranteed by all of the Companys current restricted subsidiaries, all of the Companys future restricted subsidiaries and by Holdings, and is secured by a first priority security interest in
substantially all of the Companys existing and future real and personal property, including accounts receivable, inventory, equipment, general intangibles, intellectual property, investment property, cash and a first priority pledge of the
Companys capital stock and the capital stock of the guarantor subsidiaries.



The senior secured credit facility requires the Company to comply, on a quarterly basis, with certain financial covenants, including an interest coverage ratio test and a maximum leverage ratio test, which will become more restrictive over
time. After the financial results are finalized for the year ending December 31, 2005, and each year thereafter, the Company may be obligated (based on certain leverage thresholds) to make payments on its term loan facility of up to 75% of
excess cash flow, as defined. In addition, the senior secured credit facility includes various negative covenants, including with respect to indebtedness, liens, investments, permitted businesses and transactions and other matters, as
well as certain customary representations and warranties, affirmative covenants and events of default, including payment defaults, breach of representations and warranties, covenant defaults, cross defaults to certain indebtedness, certain events of
bankruptcy, certain events under ERISA, material judgments, actual or asserted failure of any guaranty or security document supporting the senior secured credit facility to be in full force and effect and change of control. If such an event of
default occurs, the lenders under the senior secured credit facility are entitled to take various actions, including the acceleration of amounts due under the senior secured credit facility and all actions permitted to be taken by a secured
creditor. As of September 30, 2005, the Company is in compliance with all financial covenants.



Senior Floating Rate Notes



During
March 2005, Holdings issued $250 million Senior Floating Rate Notes, due 2015 (the Holdings Notes). The Holdings Notes are senior unsecured obligations that bear interest at a floating rate, reset semi-annually, equal to 6-month LIBOR
plus 5.25%. Simultaneously with the financing, Holdings entered into an interest rate swap agreement, effectively fixing the interest rate at 9.4% for a period of two years ending March 15, 2007. During the period that the interest expense has
been fixed, interest expense will amount to approximately $23.5 million annually, and may be more or less than that amount thereafter. During the third quarter of 2005, the Company paid Holdings an $11.0 million dividend to finance the semi-annual
interest payment, due September 15, 2005.



Because Holdings sole
asset is its investment in US Oncology, the Company plans to provide funds to service this indebtedness through payment of dividends to Holdings. The terms of the existing senior secured credit facility, as well as the indentures governing its
senior notes and senior subordinated notes, and certain other agreements, restrict it and certain of its subsidiaries from making payments or transferring assets to Holdings, including dividends, loans or other distributions. Such restrictions
include prohibition of dividends in an event of default and limitations on the total amount of dividends paid to Holdings. In the event these agreements do not permit the Company to provide Holdings with sufficient distributions to fund interest and
principal payments on the Holdings Notes when due, Holdings may default on its notes unless other sources of funding are available. Amounts available under this restricted payments provision amounted to $79.0 million as of September 30, 2005.



Additionally, the indenture governing the Holdings Notes contains certain
covenants that limit, among other things, the Companys ability to incur additional debt, pay dividends, redeem or repurchase capital stock, issue capital stock, make certain investments, enter into certain types of transactions with
affiliates, engage in unrelated businesses, create liens securing its debt, and sell certain assets or merge with or into other companies.



Proceeds from the Holdings Notes were used to pay a $250 million dividend to its common and preferred shareholders. The dividend payment triggered a payment obligation of
$14.5 million under Holdings Cash Incentive Plan, and Holdings also incurred approximately $7.2 million in expenses related to the offering. These amounts were financed with a dividend from the Company to Holdings during the second quarter of
2005.



-12-



---

##### Table of Contents

US ONCOLOGY, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

QUARTER ENDED SEPTEMBER 30, 2005
continued



Future principal obligations under indebtedness as of
September 30, 2005, are as follows (in thousands):



|                         |  |      |        |      |       |      |       |      |       |      |       |            |   |        
|------------------------ |  | ---- | ------ | ---- | ----- | ---- | ----- | ---- | ----- | ---- | ----- | ---------- | - | -------
|                         |  | 2006 |        | 2007 |       | 2008 |       | 2009 |       | 2010 |       | Thereafter
|US Oncology payments due |  | $    | 10,399 |      | 7,300 |      | 6,438 |      | 4,775 |      | 4,802 |            | $ | 946,494
|Holdings payments due    |  |      |       |      |      |      |      |      |      |      |      |            |   | 250,000



NOTE 6 -
STOCK-BASED COMPENSATION



The
Company has elected to continue to follow APB 25, and the related interpretations in accounting for its employee stock options. Under APB 25, because the exercise price of employee stock options is equal to or greater than the fair value of the
underlying stock on the date of grant, no compensation expense is recognized. For the quarter and nine months ended September 30, 2005, if the Company had applied the fair value recognition provisions of SFAS No. 123, the related effects
would have been immaterial to the Companys financial statements.



Successor Stock Incentive Plans



The following disclosures
relate to the stock incentive plans of the Companys parent subsequent to the August Transactions. Each of these plans involves shares of Holdings common stock or options to purchase Holdings common stock. Because these plans are for the
benefit of US Oncology, any expenses related to awards are reflected in the Companys financial statements.



The Holdings Board of Directors adopted the US Oncology Holdings, Inc. 2004 Equity Incentive Plan (the Equity Incentive Plan) effective in August,
2004. The Equity Incentive Plan provides for grants of up to 22,290,371 shares of restricted stock and 3,933,595 options to purchase Holdings common stock. The purpose of the plan is to attract and retain the best available personnel and to provide
additional incentives to employees and consultants to promote the success of the business. Holdings granted 21,580,000 shares of common stock as restricted stock awards during the period from August 21 through December 31, 2004, and
240,000 shares during the nine months ended September 30, 2005. The fair value of the restricted stock awards issued during the period from August 21 through December 31, 2004, and the nine months ended September 30, 2005, of
approximately $10.8 million and $0.4 million, respectively, was recorded as paid in capital and deferred compensation in the Statement of Stockholders Equity. Depending on the individual grants, awards vest either at the grant date, over
defined service periods, or upon achieving a return on invested capital in excess of established thresholds. Based on the individual vesting criteria for each award, the Company recorded total amortization expense of approximately $1.0 million
and $2.9 million, respectively, for the three and nine months ended September 30, 2005.



During October 2004, Holdings granted 1,820,000 options for shares of common stock to certain employees of which 1,810,000 options remained outstanding (net of forfeitures) as of December 31, 2004. For the nine
months ended September 30, 2005 the Company awarded 470,000 options. The options were granted at the fair value of Holdings common stock as of the date of grant, vest over 5 years (or upon specified performance periods during the three
years ending December 31, 2006) and have an option term not to exceed 10 years. As of September 30, 2005, 2,280,000 options are outstanding (net of forfeitures).



The Holdings Board of Directors also adopted the US Oncology Holdings 2004 Director Stock Option Plan (the Director Stock Option
Plan), which became effective in October 2004 upon Holdings stockholder approval. The total number of shares of common stock for which options may be granted under the Director Stock Option Plan is 500,000 shares. Under this plan,
each eligible director in office at the plans adoption and each eligible director who joined the board after adoption was automatically granted an option to purchase 5,000 shares of Holdings common stock at fair value. In addition, each such
director was automatically granted an option to purchase 1,000 shares of Holdings common stock for each board committee on which such director served. Through September 30, 2005, options to purchase 29,000 shares of Holdings common stock have
been granted to directors under the Director Stock Option Plan. The options vest six months after the date of grant.



-13-



---

##### Table of Contents

US ONCOLOGY, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

QUARTER ENDED SEPTEMBER 30, 2005
continued



In addition to these stock incentive plans, Holdings has adopted
the US Oncology Holdings, Inc. 2004 Long-Term Cash Incentive Plan (the Cash Incentive Plan). Under the Cash Incentive Plan, which is administered by the Compensation Committee of the Board of Directors of Holdings, awards granted to
participants provide for cash payments upon i) a qualified initial public offering or change in control of Holdings or ii) dividends on or redemptions of preferred stock. Cash payments are payable to participants based upon certain performance
objectives, as set forth in the terms, conditions and other provisions of the awards under the Cash Incentive Plan. During the first quarter of 2005, Holdings declared and paid a special dividend of $250.0 million to its common and preferred
stockholders. As a result of the dividend paid to preferred stockholders, Holdings became obligated to make a cash payment of $14.5 million under the Cash Incentive Plan that was financed with a dividend from the Company. Compensation expense
associated with this obligation was recorded in the first quarter of 2005. Payment of the dividend and the corresponding payment under the Cash Incentive Plan was made in the second quarter of 2005.



If any of the payment triggering events described in the Cash Incentive Plan should occur in
the future, the additional obligation (and compensation expense) as a result of such event or events would be approximately $6.9 million as of September 30, 2005. The amount of this obligation may increase or decrease based upon future
performance of the Company.



Predecessor Stock Incentive Plans



The following disclosures relate to the stock incentive plans of the
Company prior to the August Transactions. All such plans were terminated in connection with the August Transactions.



At August 20, 2004, the Company had seven stock-based employee compensation plans. The Company accounted for those plans under the recognition and measurement
principles of Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees, (APB 25) and related interpretations. Stock-based employee compensation costs for options granted under those plans with
exercise prices less than the market value of the underlying common stock on the date of the grant were insignificant for the period from July 1, 2004 through August 20, 2004 (predecessor) and the period from January 1, 2004 through
August 20, 2004 (predecessor).



The following table illustrates the effect
on net income if the Company had applied the fair value recognition provisions of SFAS Statement No. 123, Accounting for Stock-Based Compensation, (SFAS 123) to stock-based employee compensation (in thousands):



|                                                                                                                                           |  |                                                 |         |   |                                                   |   |         |  
|------------------------------------------------------------------------------------------------------------------------------------------ |  | ----------------------------------------------- | ------- | - | ------------------------------------------------- | - | ------- | -
|                                                                                                                                           |  | Period from July 1, 2004 through August 20,2004 |         |   | Period from January 1,2004 through August 20,2004 |  
|                                                                                                                                           |  | (Predecessor)                                   |         |   | (Predecessor)                                     |  
|Net income (loss), as reported                                                                                                             |  | $                                               | (18,349 | ) |                                                   | $ | 26,318  |  
|Less: total stock-based employee compensation expense determined under fair-value based method for all awards, net of related income
taxes |  |                                                 | (2,674  | ) |                                                   |   | (15,390 | )
|                                                                                                                                           |  |                                                 |         |   |                                                   |   |         |  
|Pro forma net income (loss)                                                                                                                |  | $                                               | (21,023 | ) |                                                   | $ | 10,928  |  
|                                                                                                                                           |  |                                                 |         |   |                                                   |   |         |  



NOTE 7 
SEGMENT FINANCIAL INFORMATION



The Company follows the provisions of SFAS No. 131, Disclosure About Segments of an Enterprise and Related Information (SFAS 131). SFAS 131 requires the utilization of a management approach to define
and report the financial results of operating segments. The management approach defines operating segments along the lines used by management to assess performance and make operating and resource allocation decisions.



The Companys reportable segments are based on internal management reporting, which
disaggregates the business by service line. The Companys reportable segments are medical oncology services, cancer center services, and



-14-



---

##### Table of Contents

US ONCOLOGY, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

QUARTER ENDED SEPTEMBER 30, 2005
continued



other services (primarily consisting of cancer research
services). The medical oncology services segment provides practice management services to medical oncology practices and purchases and manages specialty oncology pharmaceuticals. The cancer center services segment, develops and manages
comprehensive, community-based cancer centers, which integrate all aspects of outpatient cancer care, from laboratory and radiology diagnostic capabilities to chemotherapy and radiation therapy. The other services segment contracts with
pharmaceutical and biotechnology firms to provide a comprehensive range of services relating to clinical trials. Results of operations for the medical oncology services segment and other services segment include both comprehensive and service line
arrangements. The Company provides cancer center services only in comprehensive service arrangements.



The table below presents segment results for the three months ended September 30, 2005, for the period from July 1, 2004 through August 20, 2004 (predecessor) and the period from August 21, 2004
through September 30, 2004 (successor) and for the nine months ended September 30, 2005, the period from January 1, 2004 through August 20, 2004 (predecessor) and the period from August 21, 2004 through September 30,
2004 (successor), (in thousands):



|                              |  |                                                   |          |   |                       |   |         |       |  |   |                |   |  |       |         |   |  |   |          |  
|----------------------------- |  | ------------------------------------------------- | -------- | - | --------------------- | - | ------- | ----- |  | - | -------------- | - |  | ----- | ------- | - |  | - | -------- | -
|                              |  | Three Months Ended September 30, 2005 (Successor) |         
|                              |  | MedicalOncologyServices                           |          |   | CancerCenter Services |   |         | Other |  |   | CorporateCosts |   |  | Total |        
|Product revenues              |  | $                                                 | 418,724  |   |                       | $ |        |       |  | $ |               |   |  | $     |        |   |  | $ | 418,724  |  
|Service revenues              |  |                                                   | 144,504  |   |                       |   | 72,879  |       |  |   | 12,238         |   |  |       |        |   |  |   | 229,621  |  
|                              |  |                                                   |          |   |                       |   |         |       |  |   |                |   |  |       |         |   |  |   |          |  
|Total revenues                |  |                                                   | 563,228  |   |                       |   | 72,879  |       |  |   | 12,238         |   |  |       |        |   |  |   | 648,345  |  
|Operating expenses            |  |                                                   | (510,890 | ) |                       |   | (48,124 | )     |  |   | (12,068        | ) |  |       | (18,268 | ) |  |   | (589,350 | )
|Depreciation and amortization |  |                                                   | (437     | ) |                       |   | (10,446 | )     |  |   | (347           | ) |  |       | (9,712  | ) |  |   | (20,942  | )
|                              |  |                                                   |          |   |                       |   |         |       |  |   |                |   |  |       |         |   |  |   |          |  
|Income (loss) from operations |  | $                                                 | 51,901   |   |                       | $ | 14,309  |       |  | $ | (177           | ) |  | $     | (27,980 | ) |  | $ | 38,053   |  
|                              |  |                                                   |          |   |                       |   |         |       |  |   |                |   |  |       |         |   |  |   |          |  



|                              |  |                                                                |          |   |                      |   |         |       |  |   |                |   |  |       |         |   |  |   |          |  
|----------------------------- |  | -------------------------------------------------------------- | -------- | - | -------------------- | - | ------- | ----- |  | - | -------------- | - |  | ----- | ------- | - |  | - | -------- | -
|                              |  | Period from July 1, 2004 through August 20, 2004 (Predecessor) |         
|                              |  | MedicalOncology Services                                       |          |   | CancerCenterServices |   |         | Other |  |   | CorporateCosts |   |  | Total |        
|Product revenues              |  | $                                                              | 213,687  |   |                      | $ |        |       |  | $ |               |   |  | $     |        |   |  | $ | 213,687  |  
|Service revenues              |  |                                                                | 80,294   |   |                      |   | 35,075  |       |  |   | 6,559          |   |  |       |        |   |  |   | 121,928  |  
|                              |  |                                                                |          |   |                      |   |         |       |  |   |                |   |  |       |         |   |  |   |          |  
|Total revenues                |  |                                                                | 293,981  |   |                      |   | 35,075  |       |  |   | 6,559          |   |  |       |        |   |  |   | 335,615  |  
|Operating expenses            |  |                                                                | (258,812 | ) |                      |   | (23,080 | )     |  |   | (6,543         | ) |  |       | (19,989 | ) |  |   | (308,424 | )
|Depreciation and amortization |  |                                                                | (11      | ) |                      |   | (4,994  | )     |  |   | (144           | ) |  |       | (6,134  | ) |  |   | (11,283  | )
|                              |  |                                                                |          |   |                      |   |         |       |  |   |                |   |  |       |         |   |  |   |          |  
|Income (loss) from operations |  | $                                                              | 35,158   |   |                      | $ | 7,001   |       |  | $ | (128           | ) |  | $     | (26,123 | ) |  | $ | 15,908   |  
|                              |  |                                                                |          |   |                      |   |         |       |  |   |                |   |  |       |         |   |  |   |          |  



|                              |  |                                                                    |          |   |                      |   |         |       |  |   |                |   |  |       |         |   |  |   |          |  
|----------------------------- |  | ------------------------------------------------------------------ | -------- | - | -------------------- | - | ------- | ----- |  | - | -------------- | - |  | ----- | ------- | - |  | - | -------- | -
|                              |  | Period from August 21, 2004 through September 30, 2004 (Successor) |         
|                              |  | MedicalOncology Services                                           |          |   | CancerCenterServices |   |         | Other |  |   | CorporateCosts |   |  | Total |        
|Product revenues              |  | $                                                                  | 149,271  |   |                      | $ |        |       |  | $ |               |   |  | $     |        |   |  | $ | 149,271  |  
|Service revenues              |  |                                                                    | 70,063   |   |                      |   | 28,345  |       |  |   | 5,437          |   |  |       |        |   |  |   | 103,845  |  
|                              |  |                                                                    |          |   |                      |   |         |       |  |   |                |   |  |       |         |   |  |   |          |  
|Total revenues                |  |                                                                    | 219,334  |   |                      |   | 28,345  |       |  |   | 5,437          |   |  |       |        |   |  |   | 253,116  |  
|Operating expenses            |  |                                                                    | (187,947 | ) |                      |   | (18,971 | )     |  |   | (4,848         | ) |  |       | (15,283 | ) |  |   | (227,049 | )
|Depreciation and amortization |  |                                                                    | (10      | ) |                      |   | (3,650  | )     |  |   | (113           | ) |  |       | (5,146  | ) |  |   | (8,919   | )
|                              |  |                                                                    |          |   |                      |   |         |       |  |   |                |   |  |       |         |   |  |   |          |  
|Income (loss) from operations |  | $                                                                  | 31,377   |   |                      | $ | 5,724   |       |  | $ | 476            |   |  | $     | (20,429 | ) |  | $ | 17,148   |  
|                              |  |                                                                    |          |   |                      |   |         |       |  |   |                |   |  |       |         |   |  |   |          |  



-15-



---

##### Table of Contents

US ONCOLOGY, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

QUARTER ENDED SEPTEMBER 30, 2005
continued



|                                                    |  |                                                  |            |   |                      |   |          |       |  |   |                |   |  |       |         |   |  |   |            |  
|--------------------------------------------------- |  | ------------------------------------------------ | ---------- | - | -------------------- | - | -------- | ----- |  | - | -------------- | - |  | ----- | ------- | - |  | - | ---------- | -
|                                                    |  | Nine Months Ended September 30, 2005 (Successor) |           
|                                                    |  | MedicalOncology Services                         |            |   | CancerCenterServices |   |          | Other |  |   | CorporateCosts |   |  | Total |        
|Product revenues                                    |  | $                                                | 1,181,431  |   |                      | $ |         |       |  | $ |               |   |  | $     |        |   |  | $ | 1,181,431  |  
|Service revenues                                    |  |                                                  | 419,315    |   |                      |   | 217,753  |       |  |   | 35,111         |   |  |       |        |   |  |   | 672,179    |  
|                                                    |  |                                                  |            |   |                      |   |          |       |  |   |                |   |  |       |         |   |  |   |            |  
|Total revenues                                      |  |                                                  | 1,600,746  |   |                      |   | 217,753  |       |  |   | 35,111         |   |  |       |        |   |  |   | 1,853,610  |  
|Operating expenses                                  |  |                                                  | (1,444,256 | ) |                      |   | (140,801 | )     |  |   | (37,408        | ) |  |       | (53,615 | ) |  |   | (1,676,080 | )
|Compensation expense under long-term incentive plan |  |                                                  |           |   |                      |   |         |       |  |   |               |   |  |       | (14,507 | ) |  |   | (14,507    | )
|Depreciation and amortization                       |  |                                                  | (474       | ) |                      |   | (29,781  | )     |  |   | (1,064         | ) |  |       | (31,813 | ) |  |   | (63,132    | )
|                                                    |  |                                                  |            |   |                      |   |          |       |  |   |                |   |  |       |         |   |  |   |            |  
|Income (loss) from operations                       |  | $                                                | 156,016    |   |                      | $ | 47,171   |       |  | $ | (3,361         | ) |  | $     | (99,935 | ) |  | $ | 99,891     |  
|                                                    |  |                                                  |            |   |                      |   |          |       |  |   |                |   |  |       |         |   |  |   |            |  



|                              |  |                                                                   |            |   |                      |   |          |       |  |   |                |   |  |       |         |   |  |   |            |  
|----------------------------- |  | ----------------------------------------------------------------- | ---------- | - | -------------------- | - | -------- | ----- |  | - | -------------- | - |  | ----- | ------- | - |  | - | ---------- | -
|                              |  | Period from January 1, 2004 through August 20, 2004 (Predecessor) |           
|                              |  | MedicalOncology Services                                          |            |   | CancerCenterServices |   |          | Other |  |   | CorporateCosts |   |  | Total |        
|Product revenues              |  | $                                                                 | 901,616    |   |                      | $ |         |       |  | $ |               |   |  | $     |        |   |  | $ | 901,616    |  
|Service revenues              |  |                                                                   | 332,204    |   |                      |   | 159,129  |       |  |   | 32,905         |   |  |       |        |   |  |   | 524,238    |  
|                              |  |                                                                   |            |   |                      |   |          |       |  |   |                |   |  |       |         |   |  |   |            |  
|Total revenues                |  |                                                                   | 1,233,820  |   |                      |   | 159,129  |       |  |   | 32,905         |   |  |       |        |   |  |   | 1,425,854  |  
|Operating expenses            |  |                                                                   | (1,093,771 | ) |                      |   | (104,992 | )     |  |   | (29,662        | ) |  |       | (50,018 | ) |  |   | (1,278,443 | )
|Depreciation and amortization |  |                                                                   | (42        | ) |                      |   | (21,862  | )     |  |   | (638           | ) |  |       | (28,031 | ) |  |   | (50,573    | )
|                              |  |                                                                   |            |   |                      |   |          |       |  |   |                |   |  |       |         |   |  |   |            |  
|Income (loss) from operations |  | $                                                                 | 140,007    |   |                      | $ | 32,275   |       |  | $ | 2,605          |   |  | $     | (78,049 | ) |  | $ | 96,838     |  
|                              |  |                                                                   |            |   |                      |   |          |       |  |   |                |   |  |       |         |   |  |   |            |  



|                              |  |                                                                    |          |   |                      |   |         |       |  |   |                |   |  |       |         |   |  |   |          |  
|----------------------------- |  | ------------------------------------------------------------------ | -------- | - | -------------------- | - | ------- | ----- |  | - | -------------- | - |  | ----- | ------- | - |  | - | -------- | -
|                              |  | Period from August 21, 2004 through September 30, 2004 (Successor) |         
|                              |  | MedicalOncology Services                                           |          |   | CancerCenterServices |   |         | Other |  |   | CorporateCosts |   |  | Total |        
|Product revenues              |  | $                                                                  | 149,271  |   |                      | $ |        |       |  | $ |               |   |  | $     |        |   |  | $ | 149,271  |  
|Service revenues              |  |                                                                    | 70,063   |   |                      |   | 28,345  |       |  |   | 5,437          |   |  |       |        |   |  |   | 103,845  |  
|                              |  |                                                                    |          |   |                      |   |         |       |  |   |                |   |  |       |         |   |  |   |          |  
|Total revenues                |  |                                                                    | 219,334  |   |                      |   | 28,345  |       |  |   | 5,437          |   |  |       |        |   |  |   | 253,116  |  
|Operating expenses            |  |                                                                    | (187,947 | ) |                      |   | (18,971 | )     |  |   | (4,848         | ) |  |       | (15,283 | ) |  |   | (227,049 | )
|Depreciation and amortization |  |                                                                    | (10      | ) |                      |   | (3,650  | )     |  |   | (113           | ) |  |       | (5,146  | ) |  |   | (8,919   | )
|                              |  |                                                                    |          |   |                      |   |         |       |  |   |                |   |  |       |         |   |  |   |          |  
|Income (loss) from operations |  | $                                                                  | 31,377   |   |                      | $ | 5,724   |       |  | $ | 476            |   |  | $     | (20,429 | ) |  | $ | 17,148   |  
|                              |  |                                                                    |          |   |                      |   |         |       |  |   |                |   |  |       |         |   |  |   |          |  



NOTE 8 
COMMITMENTS AND CONTINGENCIES



Leases



The Company leases office space, comprehensive cancer
centers and certain equipment under noncancelable operating lease agreements. As of September 30, 2005, total future minimum lease payments, including escalation provisions and leases with entities affiliated with practices, are as follows (in
thousands):



|             |  |      |        |      |        |      |        |      |        |      |        |            |   |        
|------------ |  | ---- | ------ | ---- | ------ | ---- | ------ | ---- | ------ | ---- | ------ | ---------- | - | -------
|             |  | 2006 |        | 2007 |        | 2008 |        | 2009 |        | 2010 |        | Thereafter
|Payments due |  | $    | 56,208 |      | 49,001 |      | 39,898 |      | 33,278 |      | 26,485 |            | $ | 137,904



-16-



---

##### Table of Contents

US ONCOLOGY, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

QUARTER ENDED SEPTEMBER 30, 2005
continued



Pharmacy Distribution Initiative



The Companys 75,000 square foot distribution facility in Fort Worth, TX, was completed
during the third quarter of 2005. As of November 2, 2005, distribution operations for approximately 70% of sites had commenced. In states where distribution licenses have been obtained, the Company is currently in the process of transitioning a
majority of the remaining affiliated practices to the distribution center. All orders for these sites are processed through the distribution center while shipments are currently made from both the Companys facility and our third-party
distributor. The Company also continues to negotiate distribution arrangements with pharmaceutical manufacturers. The Companys total investment in distribution facilities and equipment is approximately $10.9 million as of September 30,
2005. Operating and one-time start-up expenses amounted to approximately $2.0 million during the nine months ended September 30, 2005. In addition, the Company expects to accumulate and maintain, on an ongoing basis, approximately $100 million
of inventory at its distribution center.



Litigation



As disclosed in Part II, Item 1, under the heading Legal Proceedings, the
Company is aware that it and certain of its subsidiaries and affiliated practices have, in the past, been subject to qui tam lawsuits filed under seal alleging healthcare law violations. Although the suits of which the Company is aware have been
dismissed, because qui tam actions are filed under seal, there is a possibility that the Company could be the subject of other qui tam actions of which it is unaware.



From time to time, the Company becomes involved in disputes with affiliated practices. These disputes typically relate to disagreements
regarding performance under the service agreement with the physician group in question or to issues of contract interpretation. Generally, the Company is able to resolve such disputes without resorting to litigation. There is a risk, however, that
such disputes could result in litigation and in a deterioration or dissolution of the relationship with the physician group in question. Currently, the Company is in litigation with one practice consisting of 35 physicians affiliated under a net
revenue model service agreement, relating to the terms of, enforceability of, and performance under, its service agreement. This practice represents 4.5% of our consolidated revenue for the nine months ended September 30, 2005.



Assessing the Companys financial and operational exposure on litigation matters
requires the application of substantial subjective judgments and estimates based upon facts and circumstances, resulting in estimates that could change as more information becomes available.



NOTE 9  RECENT ACCOUNTING
PRONOUNCEMENTS



In December 2004, the FASB issued
Statement No. 123(R), Share-Based Payment, an amendment of FASB Statements No. 123 and 95, (SFAS 123(R)) which addresses the accounting for share-based payment transactions in which an enterprise receives employee
services in exchange for either equity instruments of the enterprise or liabilities that are based on the fair value of the enterprises equity instruments or that may be settled by the issuance of such equity instruments. The proposed
statement eliminates the ability to account for share-based compensation transactions using the intrinsic value method as prescribed by the Accounting Principles Board, or APB, Opinion No. 25, Accounting for Stock Issued to
Employees, and generally requires that such transactions be accounted for using a fair-value-based method and recognized as expenses in the consolidated statement of operations and comprehensive income. The standard requires that the modified
prospective method be used, which requires that the fair value of new awards granted from the beginning of the period of adoption (plus unvested awards at the date of adoption) be expensed over the vesting period. The statement requires companies to
assess the most appropriate model to calculate the value of the options. The Company currently uses the Black-Scholes option pricing model to value options, and is currently assessing which model to use in the future under the new statement and may
deem an alternative model to be more appropriate. The use of a different model to value options may result in a different fair value than the use of the Black-Scholes option pricing model. In addition, a number of other requirements exist under the
standard that will result in differing accounting treatment than currently required. These differences include, but are not limited to, the accounting for the tax benefits on employee stock options. The effective date of the standard for nonpublic
companies is for annual fiscal periods beginning after December 15, 2005. The Company continues to evaluate the impact of the adoption of this standard, but does not expect the adoption of SFAS 123(R) to have a material effect on its results of
operations or financial position.



-17-



---

##### Table of Contents

US ONCOLOGY, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

QUARTER ENDED SEPTEMBER 30, 2005
continued



In June 2005, the FASB issued SFAS No. 154,
Accounting Changes and Error Corrections, (SFAS No. 154) which changes the requirements for accounting for and reporting of a change in accounting principle. SFAS No. 154 requires retrospective application to prior
periods financial statements of a voluntary change in accounting principle unless it is impracticable. SFAS No. 154 also requires that a change in method of depreciation, amortization, or depletion for long-lived, non-financial assets be
accounted for as a change in accounting estimate that is affected by a change in accounting principle. SFAS No. 154 is effective for accounting changes and corrections of errors made in fiscal years beginning after December 15, 2005, but
does not change the transition provisions of any existing accounting pronouncements, including those that are in a transition phase as of the effective date of SFAS No. 154. The adoption of SFAS No. 154 is not expected to have a material
effect on the Companys results of operations or financial position.



-18-



---

##### Table of Contents

US ONCOLOGY, INC.

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF

OPERATIONS



ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS



Introduction



The following discussion should be read in conjunction with the financial statements, related notes, and other financial information appearing elsewhere in this report. In addition, see Forward-Looking
Statements and Risk Factors included in Amendment No. 2 to our Registration Statement on Form S-4, filed with the SEC on March 16, 2005, and subsequent filings.



General



We provide comprehensive services to our network of affiliated practices, made up of 985 affiliated physicians in 494 locations, with the mission of expanding access to
and improving the quality of cancer care in local communities. The services we offer include:



| |  | Medical Oncology Services.Under our physician practice management arrangements, we act as the exclusive manager and administrator of all day-to-day non-medical business
functions connected with our affiliated practices. As such, we are responsible for billing and collecting for medical oncology services, physician recruiting, data management, accounting, systems and capital allocation to facilitate growth in
practice operations. We also purchase and manage specialty oncology pharmaceuticals for our affiliated practices. Annually, we are responsible for purchasing, delivering and managing more than $1.4 billion of pharmaceuticals through a network of 46
licensed pharmacies, 158 pharmacists and 317 pharmacy technicians.
|- |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  | Cancer Center Services.We develop and manage comprehensive, community-based cancer centers, which integrate all aspects of outpatient cancer care, from laboratory and
radiology diagnostic capabilities to chemotherapy and radiation therapy. We have developed and operate 97 community-based radiation facilities, including 84 integrated cancer centers that include medical oncology and radiation oncology operations,
and 13 radiation-only facilities. We manage over one million square feet of medical office space. We also have installed and manage 30 Positron Emission Tomography (PET) systems including 8 Positron Emission Tomography/Computerized
Tomography (PET/CT) systems.
|- |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  | Cancer Research Services.We facilitate a broad range of cancer research and development activities through our network. We contract with pharmaceutical and biotechnology
firms to provide a comprehensive range of services relating to clinical trials. We currently supervise 72 clinical trials supported by our network of 492 participating physicians in more than 186 research locations.
|- |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



We provide these services through two economic models: a comprehensive services model, under
which we provide all of the above services under a single contract with one fee based on overall performance; and our pharmaceutical service line model, under which medical oncology practices contract with the Company to purchase only the
pharmaceutical aspects of medical oncology services. Most of our revenues (approximately 89% during the third quarter of 2005) are derived under the comprehensive services model.



The Merger Transaction



On August 20, 2004, Oiler Acquisition Corp., a wholly-owned subsidiary of US Oncology Holdings, Inc. (Holdings) merged with and into US Oncology,
with US Oncology continuing as the surviving corporation and a wholly-owned subsidiary of Holdings. The merger transaction was valued at approximately $1.6 billion. The merger and related transactions are referred to in this report as the
Merger or August Transactions.



Prior to the merger,
14,307,501 shares of US Oncology common stock then owned by Welsh, Carson, Anderson & Stowe IX, L.P. (WCAS) and its affiliates, with a fair value of $215.3 million, were contributed to Holdings in exchange for shares of
Holdings common and participating preferred stock. Upon consummation of the merger, these common shares were cancelled without payment of any merger consideration. The Company repaid approximately $281.1 million of existing indebtedness and
incurred approximately $104.4 million in fees and expenses in connection with the August Transactions.



-19-



---

##### Table of Contents

US ONCOLOGY, INC.

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF

OPERATIONS
continued



The August Transactions were
financed by:



| |  |  | a cash common and preferred equity investment in Holdings by WCAS and its related equity investors of $302.4 million, which funds were contributed to US Oncology;
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the borrowing by US Oncology of $400.0 million in term loans under its new senior secured credit facility;
| | - |  | ----------------------------------------------------------------------------------------------------------



| |  |  | $245.0 million of cash on hand at the closing date; and
| | - |  | -------------------------------------------------------



| |  |  | the issuance by US Oncology of $300.0 million aggregate principal amount of senior notes and $275.0 million aggregate principal amount of senior subordinated notes.
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------



The August Transactions were accounted for under the purchase
method of accounting prescribed in Statement of Financial Accounting Standards (SFAS) No. 141, Business Combination, (SFAS No. 141), with intangible assets recorded in accordance with SFAS No. 142,
Goodwill and Other Intangible Assets (SFAS No. 142). The purchase price, including transaction-related fees, was allocated to the Companys tangible and identifiable intangible assets and liabilities based upon estimates of
fair value, with the remainder allocated to goodwill.



Subsequent to the
initial capitalization of the Company, additional capital contributions of $39.8 million were received from Holdings. The contributions represent the proceeds from private equity offerings to certain affiliated physicians and employees of the
Company and to certain members of management.



Our Strategy



Our mission is to increase access to and advance the delivery of high-quality cancer care
in America. We do this by offering services to physicians that enable them to provide cancer patients with a full continuum of care, including professional medical services, chemotherapy infusion, radiation oncology, diagnostic services, access to
clinical trials, patient education and other services, primarily in a community setting. We aim to enhance efficiency and lower cost structures at our affiliated practices, while enabling them to continue to deliver quality patient care.



We believe that today, particularly in light of recent changes in Medicare reimbursement
and continued pressures on overall reimbursement, the most successful oncology practices will be those practices which have a preeminent position in their local market, that are diversified beyond medical oncology and that have implemented efficient
management processes. We believe that our services best position practices to attain these characteristics. At the same time, the economics of healthcare and the aging of the American population mean that pressures to reduce health care costs and
increase efficiency of medical practice operations will continue. We believe that community-based oncology care is the most patient-friendly and cost-effective care available, and we believe that we can continue to enhance practice efficiency within
the community context.



In all of our practices, we continue to focus on
initiatives that enhance efficiency by sharing best practices regarding efficient practice management, pharmaceutical use, practice staffing and other strategies across our network. In addition, we assist our practices in their implementation of
programs designed to enhance the quality and convenience of patient care. We also manage the development of additional practice sites and assist practices in maintaining adequate reimbursement rates.



During 2004 we acquired electronic medical record software, iKnowMed, along with its
technical development team and related assets located in Berkeley, CA. We have commenced implementation of iKnowMed at selected affiliated practices. We believe that continued implementation of information systems and analytical tools at our
affiliated practices will improve patient care, efficiency, and our ability to provide information services. We may make additional acquisitions to expand our range of services and further our growth initiatives.



As part of our strategy to broaden the range of services offered to affiliated practices, we
are developing a specialty pharmaceutical distribution operation. We have completed the buildout of our 75,000 square foot distribution facility in Fort Worth, TX, and obtained necessary distribution licenses for certain states during the first nine
months of 2005. As of November 2, 2005, distribution operations for approximately 70% of sites had commenced.



-20-



---

##### Table of Contents

US ONCOLOGY, INC.

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF

OPERATIONS
continued



In states where distribution licenses have been obtained, the
Company is currently in the process of transitioning a majority of the remaining affiliated practices to the distribution center. We also continue to negotiate distribution arrangements with pharmaceutical manufacturers. During the phase-in of our
distribution function, all orders are processed through the distribution center while shipments are currently made from both our distribution facility and our third-party distributor. The Company anticipates the networks affiliated practices
will receive approximately 90% of their pharmaceuticals from the distribution facility by the end of the first quarter of 2006. We believe our own distribution operation will give us an opportunity to enhance efficiency within our network, and will
afford us the opportunity to ensure the safety and authenticity of drugs used by our practices as a result of our control of the pharmaceuticals directly from the manufacturer to the patient. We also intend to continue to expand other services we
provide to pharmaceutical manufacturers.



Our total investment in distribution
facilities and equipment is approximately $10.9 million as of September 30, 2005. Operating and one-time start-up expenses amounted to approximately $2.0 million during the nine months ended September 30, 2005. In addition, we expect to
accumulate and maintain, on an ongoing basis, approximately $100 million of inventory at the distribution center. We expect to make this investment during the remainder of 2005 and the first quarter of 2006 from available cash generated from
operations and, if necessary, borrowings under our existing revolving line of credit.



Another key initiative is expanding our network. We plan to grow in two ways. First, we seek to enter into comprehensive service agreements with practices in new markets, including those where we already have a regional presence. By seeking
new markets we can grow our national presence while taking advantage of the efficiencies that result from leveraging existing regional and national infrastructure and capabilities. Second, we intend to expand our existing markets both by assisting
practices with individual physician recruitment and by affiliating or facilitating affiliation with already established practices. On a local level, this helps our affiliated practices solidify their standing in local communities, while taking
advantage of efficiencies that result from leveraging existing local assets and infrastructure.



Economic Models



Our comprehensive
service agreements are long-term agreements (generally with initial terms of 25 to 40 years), cannot be terminated unilaterally without cause and physicians are required to enter into employment or non-competition agreements with the practice. Prior
to 2002 and to a limited extent in 2005, we paid consideration to physicians in physician groups in exchange for the groups selling us operating assets and entering into such long-term contracts or joining an already affiliated group. Historically,
we also have assisted affiliated groups expand by recruiting individual physicians without buying assets or paying consideration for service agreements. We intend to continue to expand our business, both by recruiting new physicians and by
affiliating with new groups.



Under the majority of our comprehensive service
agreements, we are compensated on the earnings model (as contrasted with the net revenue model). Under this model, we are reimbursed for all expenses we incur in connection with managing a practice, and are paid an additional
fee based upon a percentage of the practices earnings before income taxes, subject to certain adjustments. During the third quarter of 2005, 81.5% of our revenue was derived from affiliated practices managed under agreements under the earnings
model. In some states, our agreements provide for a fixed management fee.



Of
our revenue for the quarter ended September 30, 2005, 7.5% was derived from comprehensive service agreements under the net revenue model, in which our fee consists of a fixed amount, plus a percentage of net revenues, plus, if certain
performance criteria are met, a performance fee. Under these agreements, once we have been reimbursed for expenses, the practice is entitled to retain a fixed portion of revenues before any additional service fee is paid to us. The effect of this
priority of payments is that we bear a disproportionate share of increasing practice costs, since, if insufficient funds exist to pay both our fee and the fixed amount to be retained by the practice, the entire amount of the shortfall reduces our
management fee. Rapidly increasing pharmaceutical costs have increased practice revenues and thus the amounts retained by physicians. At the same time rising costs have eroded margins, leaving less available to pay our management fees.



-21-



---

##### Table of Contents

US ONCOLOGY, INC.

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF

OPERATIONS
continued



Since 2000, we have been seeking to convert net revenue model
practices to the earnings model or service line model. Related to this effort, we have also terminated our relationship with several practices where we have been unable to come to terms regarding a conversion. During the year ended December 31,
2000, 56.3% of our revenue was derived from net revenue model practices, while only 7.5% of our 2005 third quarter revenue was so derived. We are currently involved in litigation with a net revenue model practice accounting for 4.5% of our 2005
third quarter revenue, in which that practice is seeking to terminate its agreement with us.



Approximately 10.5% of our third quarter 2005 revenue was derived under the service line model. Under our service line agreements, fees include payment for pharmaceuticals and supplies used by the group, reimbursement
for certain pharmacy-related expenses and payment for the other services we provide. Fees for our services are based on the level of services provided to each practice.



Forward-Looking Statements and Risk Factors



The following statements are or may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995: (i) certain
statements, including possible or assumed future results of operations contained in Managements Discussion and Analysis of Financial Condition and Results of Operations, (ii) any statements contained herein regarding the
prospects for any of our business or services and our development activities relating to physician affiliations, cancer centers and PET installations; (iii) any statements preceded by, followed by or that include the words believes,
expects, anticipates, intends, estimates, plans or similar expressions; and (iv) other statements contained herein regarding matters that are not historical facts.



Our business and results of operations are subject to risks and uncertainties, many of which
are beyond managements ability to control or predict. Because of these risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements, and investors are cautioned not to place
undue reliance on such statements, which speak only as of the date thereof.



Additional risks and uncertainties relating to our operations include Medicare reimbursement for prescription drugs used by affiliated practices, including continued implementation of the Medicare Modernization Act of 2003
(MMA), calculation of average sales price, implementation of third-party vendor programs and other matters, impact of ASP-based reimbursement on other aspects of our business (such as private payor reimbursement, our ability to obtain
favorable pharmaceutical pricing, the ability of practices to continue offering chemotherapy services to Medicare patients or maintaining existing practice sites, physician response to the legislation, including with respect to retirement or choice
of practice setting, development activities, and the possibility of additional impairments of assets, including management services agreements), concentration of pharmaceutical purchases and favorable pricing among a limited number of vendors,
reimbursement for pharmaceutical products generally, our ability to maintain good relationships with existing practices, our ability to successfully implement our strategic initiatives, (such as entry into pharmaceutical distribution and
implementation of our iKnowMed medical record system, expansion into new markets and development of existing markets), our ability to continue to comply with restrictive covenants in our debt agreements, our ability to complete cancer centers and
PET facilities currently in development, our ability to recover the costs of our investments in cancer centers, our ability to complete negotiations and enter into agreements with practices currently negotiating with us, reimbursement for
health-care services, continued efforts by payors to lower their costs, government regulation and enforcement, continued relationships with pharmaceutical companies and other vendors, changes in cancer therapy or the manner in which care is
delivered, drug utilization, increases in the cost of providing cancer treatment services and the operations of the companys affiliated physician practices.



Reductions in Medicare reimbursement, including those related to MMA, may also cause some oncologists to cease providing care in the
physician office setting either by retiring from the practice of medicine, by moving to a hospital setting or (beginning in mid-2006) by choosing to obtain drugs through the Medicare competitive acquisition program. Any reduction in the number of
our affiliated practices would adversely affect our results of operations. In addition, any reduction in the overall size of the outpatient oncology market could adversely affect our prospects for growth and business development. We believe that the
increasing budget deficit, aging U.S. population and newly enacted prescription drug benefit will mean that pressure to reduce health care costs, drug costs in particular, will continue to intensify.



-22-



---

##### Table of Contents

US ONCOLOGY, INC.

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF

OPERATIONS
continued



Please refer to our filings with the SEC, including Amendment
No. 2 to our Registration Statement on Form S-4, filed with the SEC on March 16, 2005, and subsequent filings, for a more extensive discussion of factors that could cause actual results to differ materially from our expectations.



The cautionary statements contained or referred to in this report should be
considered in connection with any written or oral forward-looking statements that may be issued by us or persons acting on our behalf. We do not undertake any obligation to release any revisions to or to update publicly any forward-looking
statements to reflect events or circumstances after the date thereof or to reflect the occurrence of unanticipated events.



Reimbursement Matters



Effective January 1, 2005, Medicare changed the method by which it reimburses providers for oncology pharmaceuticals administered in physicians offices, including those in the US Oncology network. Medicare
now pays oncologists the average sales price (ASP) for drugs plus 6%. Previously, Medicare reimbursed physicians for oncology pharmaceuticals based on average wholesale price (AWP), which is significantly higher than ASP.
This shift in reimbursement methodology represented approximately a 15% reduction in reimbursement for oncology pharmaceuticals paid during the first quarter of 2005, as compared to 2004 levels.



Since implementation, ASP has not remained constant. ASP for the third quarter of 2005
resulted in a further reduction in Medicare reimbursement for pharmaceuticals administered by affiliated practices of approximately 2% from the second quarter of 2005 and, similarly, ASP for the fourth quarter is expected to result in a further
reduction of 1% from the third quarter of 2005. For the nine months ended September 30, 2005, we have experienced approximately a 7% decrease in Medicare reimbursement since January 1. The adverse impact of ASP implementation, including
the further reduction in the fourth quarter, has been partially mitigated by the overall growth of affiliated practices revenues. Published ASP for the fourth quarter of 2005, if applied to pharmaceuticals administered by affiliated practices
during the third quarter of 2005 would result in a decrease of approximately $0.5 million in EBITDA, for the third quarter of 2005.



The decline in oncology pharmaceutical reimbursement has been partially offset by payments for certain data relating to symptom management for cancer patients (the
Medicare Demonstration Project). For 2005, the Medicare Demonstration Project was projected by CMS to add an aggregate of $260 million in Medicare payments to oncologists across the United States. CMS recently announced the continuation of the
project for 2006. The continuation includes substantial revisions to the program to gather more specific information relevant to the quality of care for cancer patients. Reporting will no longer be specific to chemotherapy, but instead will be
focused on physician evaluation and management. We are working to evaluate and clarify the impact of program revisions. We currently expect that reduced reimbursement under the Medicare Demonstration Project will negatively impact EBITDA in 2006 by
approximately $5-6 million (based on application of revised rates to our 2005 results).



Adoption of ASP pricing by Medicare, combined with the importance of pharmaceuticals to our business and concentration of our purchases with a limited number of manufacturers, represents a significant risk for the
Company. Nearly all of our pricing advantage relative to ASP is derived from purchases of drugs from a small number of manufacturers. We believe that implementation of ASP-based pricing will likely reduce the amount of differential pricing that is
available to us in the marketplace, which is one of our key competitive strengths.



On July 6, 2005, the Centers for Medicare and Medicaid Services (CMS) introduced an Interim Final Rule on the Competitive Acquisition Program (CAP), scheduled to begin January 1, 2006. Under CAP, physician
practices may opt to have an external vendor provide and bill Medicare for the drugs and biologicals administered in the physicians office. On August 3, 2005 CMS announced that bidding under CAP had been postponed pending further
revisions to the program rules. On November 2, 2005, certain aspects of the CAP were revised in two rules. A final rule contains revisions aimed at improving a number of the components of CAP including the bidding process and certain
operational issues. An interim final rule with comment period excludes the sales of drugs furnished under the CAP in the Average Sales Price calculations for a period of three years.



Medicare reimbursement for services of physicians is based on a fee schedule, which
establishes payment for a given service, in relation to actual resources used in providing the service, through the application of relative value units (RVUs or units). RVUs are intended to reflect the intensity
of the physicians work, practice expenses and



-23-



---

##### Table of Contents

US ONCOLOGY, INC.

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF

OPERATIONS
continued



geographic variations in costs. The units are converted into a
dollar amount of reimbursement through a conversion factor. CMS updates the conversion factor each year based on a formula. For 2006, application of the formula results in a 4.4% decrease in the conversion factor, and when combined with a
modification for budget neutrality, the conversion factor is slated to decrease by 4.5%. Through the MMA, Congress has legislated that the conversion factor for 2004 and 2005 would increase by 1.5% per year. For 2006, the Senate has passed
legislation that includes a 1% increase in the conversion factor. The House has not included such language in its reconciliation package. Lawmakers will meet in conference committee to resolve differences between the House and Senate versions of the
bills. It is expected that the conversion factor will be finalized by the end of 2005.



If Congress does not revise the formula-derived conversion factor between now and year end, Medicare reimbursement for physician services will decrease by 4.5 %, effective January 1, 2006. If applied to annualized
September 30, 2005 reimbursements, a decrease of 4.5% would reduce EBITDA by $4-5 million for the year ending December 31, 2005. Also, there is a likelihood that if Congress does not act on the conversion factor, reimbursement for
some managed care contracts would decrease similarly.



Critical Accounting
Policies and Estimates



Our discussion and analysis of our financial
condition and results of operations are based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim
financial statements. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and
liabilities. On an ongoing basis, we evaluate these estimates, including those related to service agreements, accounts receivable, intangible assets, goodwill, income taxes, and contingencies and litigation. We base our estimates on historical
experience and on various other assumptions that we believe to be reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other
sources.



Actual results may differ from those estimates under different
assumptions or conditions. In addition, as circumstances change, we may revise the basis of our estimates accordingly. For example, in the past we have recorded charges to reflect revisions in our valuation of accounts receivable as a result of
actual collection patterns. We maintain decentralized billing systems and continue to upgrade and modify those systems. We take this into account as we evaluate the realizability of receivables and record appropriate reserves, based upon the risks
of collection inherent in such a structure. In the event subsequent collections are higher or lower than our estimates, results of operations in subsequent periods could be either positively or negatively impacted as a result of such prior
estimates. This risk is particularly relevant for periods in which there is a significant shift in reimbursement from large payors, such as the recent changes in Medicare reimbursement.



Please refer to the Critical Accounting Policies section of Amendment No. 2 to our Registration Statement on Form S-4,
filed with the SEC on March 16, 2005, and subsequent filings, for a discussion of our critical accounting policies. Management believes such critical accounting policies affect the more significant judgments and estimates used in the
preparation of our consolidated condensed financial statements. These critical accounting policies include our policy of non-consolidation of the results of affiliated practices, revenue recognition, general estimates of accruals, including accruals
relating to accounts receivable, and intangible asset amortization and impairment.



Recent Accounting Pronouncements



In December 2004, the
FASB issued Statement No. 123(R), Share-Based Payment, an amendment of FASB Statements No. 123 and 95, (SFAS 123(R)) which addresses the accounting for share-based payment transactions in which an enterprise
receives employee services in exchange for either equity instruments of the enterprise or liabilities that are based on the fair value of the enterprises equity instruments or that may be settled by the issuance of such equity instruments. The
proposed statement eliminates the ability to account for share-based compensation transactions using the intrinsic value method as prescribed by the Accounting Principles Board, or APB, Opinion No. 25, Accounting for Stock Issued to
Employees, and generally requires that such transactions be accounted for using a fair-value-based method and recognized as expenses in the consolidated statement of operations and comprehensive



-24-



---

##### Table of Contents

US ONCOLOGY, INC.

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF

OPERATIONS
continued



income. The standard requires that the modified prospective
method be used, which requires that the fair value of new awards granted from the beginning of the period of adoption (plus unvested awards at the date of adoption) be expensed over the vesting period. The statement requires companies to assess the
most appropriate model to calculate the value of the options. The Company currently uses the Black-Scholes option pricing model to value options, and is currently assessing which model to use in the future under the new statement and may deem an
alternative model to be more appropriate. The use of a different model to value options may result in a different fair value than the use of the Black-Scholes option pricing model. In addition, a number of other requirements exist under the standard
that will result in differing accounting treatment than currently required. These differences include, but are not limited to, the accounting for the tax benefits on employee stock options. The effective date of the standard for nonpublic companies
is for annual fiscal periods beginning after December 15, 2005. We continue to evaluate the impact of the adoption of this standard, but does not expect the adoption of SFAS 123(R) to have a material effect on our results of operations or
financial position.



In June 2005, the FASB issued SFAS No. 154,
Accounting Changes and Error Corrections, (SFAS No. 154) which changes the requirements for accounting for and reporting of a change in accounting principle. SFAS No. 154 requires retrospective application to prior
periods financial statements of a voluntary change in accounting principle unless it is impracticable. SFAS No. 154 also requires that a change in method of depreciation, amortization, or depletion for long-lived, non-financial assets be
accounted for as a change in accounting estimate that is affected by a change in accounting principle. SFAS No. 154 is effective for accounting changes and corrections of errors made in fiscal years beginning after December 15, 2005, but
does not change the transition provisions of any existing accounting pronouncements, including those that are in a transition phase as of the effective date of SFAS No. 154. The adoption of SFAS No. 154 is not expected to have a material
effect on our results of operations or financial position.



From time to time,
the FASB, the SEC and other regulatory bodies seek to change accounting rules, including rules applicable to our business and financial statements. We cannot assure you that future changes in accounting rules would not require us to make
restatements.



Discussion of Non-GAAP Information



In this quarterly report, we use the term EBITDA which represents earnings
before interest and other expense, net, taxes, depreciation, amortization (including amortization of stock compensation). EBITDA is not calculated in accordance with GAAP, rather it is derived from relevant items in our GAAP-based financial
statements. A reconciliation of EBITDA to the income statement and statement of cash flows is included in this document.



We believe EBITDA is useful to investors in evaluating the value of companies in general, and in evaluating the performance and liquidity of companies with debt service
obligations and their ability to service their indebtedness. Management uses EBITDA as a key indicator to evaluate our liquidity and financial condition, both with respect to the business as a whole and with respect to individual sites in our
network. Our senior secured credit facility also requires that we comply on a quarterly basis with certain financial covenants that include EBITDA as a financial measure. Management believes that EBITDA is useful to investors, since it provides
investors with additional information that is not directly available in a GAAP presentation.



Also within this quarterly report, to facilitate comparison of the quarterly and nine month periods ended September 30, financial results preceding the August Transactions have been combined with results
following the August Transactions. Such combination is not consistent with GAAP, which requires the successor period be presented separately from the predecessor period, because purchase accounting adjustments may make the successor period not
comparable to the predecessor period.



In all events, EBITDA and the combined
results for the quarterly and nine month periods ended September 30, 2004, are not intended to be a substitute for GAAP measures, and investors are advised to review such non-GAAP measures in conjunction with GAAP information provided by us.



-25-



---

##### Table of Contents

US ONCOLOGY, INC.

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF

OPERATIONS
continued



Results of Operations



As of September 30, 2005 and 2004, respectively, we have affiliated with the following
number of physicians (including those under service line arrangements), by specialty:



|                                  |  |                   |  |                  
|--------------------------------- |  | ----------------- |  | -----------------
|                                  |  | September 30,2005 |  | September 30,2004
|Medical oncologists/hematologists |  | 805               |  | 782              
|Radiation oncologists             |  | 140               |  | 127              
|Other oncologists                 |  | 40                |  | 38               
|                                  |  |                   |  |                  
|Total physicians                  |  | 985               |  | 947              
|                                  |  |                   |  |                  



The following tables set forth the
sources of growth in the number of physicians affiliated with the Company under both comprehensive and service line agreements:



|                                           |  |                                    |   |  |                                            |   |  |                                   |   |  |                                           |  
|------------------------------------------ |  | ---------------------------------- | - |  | ------------------------------------------ | - |  | --------------------------------- | - |  | ----------------------------------------- | -
|Comprehensive Service Agreements           |  | Three MonthsEndedSeptember 30,2005 |   |  | CombinedThree MonthsEndedSeptember 30,2004 |   |  | Nine MonthsEndedSeptember 30,2005 |   |  | CombinedNine MonthsEndedSeptember 30,2004 |  
|Affiliated physicians, beginning of period |  | 803                                |   |  | 805                                        |   |  | 797                               |   |  | 793                                       |  
|Physician practice affiliations            |  | 10                                 |   |  | 5                                          |   |  | 27                                |   |  | 8                                         |  
|Recruited physicians                       |  | 45                                 |   |  | 29                                         |   |  | 54                                |   |  | 50                                        |  
|Physician practice separations             |  |                                   |   |  |                                           |   |  | (5                                | ) |  | (2                                        | )
|Retiring/Other                             |  | (17                                | ) |  | (12                                        | ) |  | (32                               | ) |  | (22                                       | )
|                                           |  |                                    |   |  |                                            |   |  |                                   |   |  |                                           |  
|Affiliated physicians, end of period       |  | 841                                |   |  | 827                                        |   |  | 841                               |   |  | 827                                       |  
|                                           |  |                                    |   |  |                                            |   |  |                                   |   |  |                                           |  



|                                           |  |                                    |   |  |                                            |   |  |                                   |   |  |                                           |  
|------------------------------------------ |  | ---------------------------------- | - |  | ------------------------------------------ | - |  | --------------------------------- | - |  | ----------------------------------------- | -
|Service Line Agreements                    |  | Three MonthsEndedSeptember 30,2005 |   |  | CombinedThree MonthsEndedSeptember 30,2004 |   |  | Nine MonthsEndedSeptember 30,2005 |   |  | CombinedNine MonthsEndedSeptember 30,2004 |  
|Affiliated physicians, beginning of period |  | 141                                |   |  | 109                                        |   |  | 133                               |   |  | 104                                       |  
|Physician practice affiliations            |  | 9                                  |   |  | 24                                         |   |  | 22                                |   |  | 40                                        |  
|Recruited physicians                       |  |                                   |   |  |                                           |   |  | 2                                 |   |  |                                          |  
|Physician practice separations             |  | (4                                 | ) |  | (7                                         | ) |  | (11                               | ) |  | (18                                       | )
|Retiring/Other                             |  | (2                                 | ) |  | (6                                         | ) |  | (2                                | ) |  | (6                                        | )
|                                           |  |                                    |   |  |                                            |   |  |                                   |   |  |                                           |  
|Affiliated physicians, end of period       |  | 144                                |   |  | 120                                        |   |  | 144                               |   |  | 120                                       |  
|                                           |  |                                    |   |  |                                            |   |  |                                   |   |  |                                           |  



-26-



---

##### Table of Contents

US ONCOLOGY, INC.

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF

OPERATIONS
continued



|The | following table sets forth the number of radiation oncology facilities and PET systems managed by us:
|--- | -----------------------------------------------------------------------------------------------------



|                                                  |  |                                    |  |                                            |  |                                   |  |                                           |  
|------------------------------------------------- |  | ---------------------------------- |  | ------------------------------------------ |  | --------------------------------- |  | ----------------------------------------- | -
|                                                  |  | Three MonthsEndedSeptember 30,2005 |  | CombinedThree MonthsEndedSeptember 30,2004 |  | Nine MonthsEndedSeptember 30,2005 |  | CombinedNine MonthsEndedSeptember 30,2004 |  
|Cancer Centers, beginning of period               |  | 82                                 |  | 77                                         |  | 79                                |  | 78                                        |  
|Cancer Centers opened                             |  | 2                                  |  | 1                                          |  | 5                                 |  | 1                                         |  
|Cancer Centers closed                             |  |                                   |  |                                           |  |                                  |  | (1                                        | )
|                                                  |  |                                    |  |                                            |  |                                   |  |                                           |  
|Cancer Centers, end of period                     |  | 84                                 |  | 78                                         |  | 84                                |  | 78                                        |  
|                                                  |  |                                    |  |                                            |  |                                   |  |                                           |  
|Radiation oncology-only facilities, end of period |  | 13                                 |  | 12                                         |  | 13                                |  | 12                                        |  
|                                                  |  |                                    |  |                                            |  |                                   |  |                                           |  
|Total Radiation Oncology Facilities               |  | 97                                 |  | 90                                         |  | 97                                |  | 90                                        |  
|                                                  |  |                                    |  |                                            |  |                                   |  |                                           |  
|PET Systems(1)                                    |  | 30                                 |  | 26                                         |  | 30                                |  | 26                                        |  
|                                                  |  |                                    |  |                                            |  |                                   |  |                                           |  

---

|(1) | Including 8 and 3 PET/CT systems at September 30, 2005 and 2004, respectively
|--- | -----------------------------------------------------------------------------



The following table sets forth the key operating statistics as a measure of the volume of services provided by our practices affiliated
under comprehensive service arrangements per operating day:



|                                                   |  |                                    |  |                                            |  |                                   |  |                                          
|-------------------------------------------------- |  | ---------------------------------- |  | ------------------------------------------ |  | --------------------------------- |  | -----------------------------------------
|                                                   |  | Three MonthsEndedSeptember 30,2005 |  | CombinedThree MonthsEndedSeptember 30,2004 |  | Nine MonthsEndedSeptember 30,2005 |  | CombinedNine MonthsEndedSeptember 30,2004
|Per Operating Day:                                 |  |                                    |  |                                            |  |                                   |  |                                          
|Medical oncology visits(1)                         |  | 9,342                              |  | 9,242                                      |  | 9,300                             |  | 9,192                                    
|Radiation treatments                               |  | 2,751                              |  | 2,524                                      |  | 2,813                             |  | 2,514                                    
|IMRT treatments (included in radiation treatments) |  | 397                                |  | 268                                        |  | 410                               |  | 240                                      
|PET scans                                          |  | 155                                |  | 114                                        |  | 148                               |  | 107                                      
|CT scans                                           |  | 591                                |  | 450                                        |  | 561                               |  | 403                                      
|New patients enrolled in research studies          |  | 888                                |  | 741                                        |  | 2,633                             |  | 2,202                                    

---

|(1) | Medical Oncology visits include those made by medical oncologists under CSA agreements only and do not include those visits made by service line physicians.
|--- | ------------------------------------------------------------------------------------------------------------------------------------------------------------



-27-



---

##### Table of Contents

US ONCOLOGY, INC.

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF

OPERATIONS
continued



The following table sets forth the percentages of revenue
represented by certain items reflected in our Condensed Consolidated Statement of Operations and Comprehensive Income. The following information should be read in conjunction with our unaudited condensed consolidated financial statements and notes
thereto included elsewhere herein.



|                                                    |  |                                    |   |  |                                            |    |  |                                   |   |  |                                           |  
|--------------------------------------------------- |  | ---------------------------------- | - |  | ------------------------------------------ | -- |  | --------------------------------- | - |  | ----------------------------------------- | -
|                                                    |  | Three MonthsEndedSeptember 30,2005 |   |  | CombinedThree MonthsEndedSeptember 30,2004 |    |  | Nine MonthsEndedSeptember 30,2005 |   |  | CombinedNine MonthsEndedSeptember 30,2004 |  
|Product revenues                                    |  | 64.6                               | % |  | 61.7                                       | %  |  | 63.7                              | % |  | 62.6                                      | %
|Service revenues                                    |  | 35.4                               |   |  | 38.3                                       |    |  | 36.3                              |   |  | 37.4                                      |  
|                                                    |  |                                    |   |  |                                            |    |  |                                   |   |  |                                           |  
|Total revenues                                      |  | 100.0                              |   |  | 100.0                                      |    |  | 100.0                             |   |  | 100.0                                     |  
|                                                    |  |                                    |   |  |                                            |    |  |                                   |   |  |                                           |  
|Cost of products                                    |  | 61.8                               |   |  | 58.6                                       |    |  | 60.9                              |   |  | 58.6                                      |  
|Cost of services:                                   |  |                                    |   |  |                                            |    |  |                                   |   |  |                                           |  
|Operating compensation and benefits                 |  | 16.6                               |   |  | 16.6                                       |    |  | 16.7                              |   |  | 17.1                                      |  
|Other operating costs                               |  | 9.7                                |   |  | 9.8                                        |    |  | 9.9                               |   |  | 10.1                                      |  
|Depreciation and amortization                       |  | 2.6                                |   |  | 2.5                                        |    |  | 2.7                               |   |  | 2.6                                       |  
|                                                    |  |                                    |   |  |                                            |    |  |                                   |   |  |                                           |  
|Total cost of services                              |  | 28.9                               |   |  | 28.9                                       |    |  | 29.3                              |   |  | 29.8                                      |  
|Total cost of products and services                 |  | 90.7                               |   |  | 87.5                                       |    |  | 90.2                              |   |  | 88.4                                      |  
|General and administrative expense                  |  | 2.8                                |   |  | 3.2                                        |    |  | 2.9                               |   |  | 2.9                                       |  
|Compensation expense under long-term incentive plan |  |                                   |   |  |                                           |    |  | 0.8                               |   |  |                                          |  
|Merger-related charges                              |  |                                   |   |  | 2.7                                        |    |  |                                  |   |  | 1.0                                       |  
|Depreciation and amortization                       |  | 0.6                                |   |  | 0.9                                        |    |  | 0.7                               |   |  | 0.9                                       |  
|                                                    |  |                                    |   |  |                                            |    |  |                                   |   |  |                                           |  
|Total costs and expenses                            |  | 94.1                               |   |  | 94.3                                       |    |  | 94.6                              |   |  | 93.2                                      |  
|                                                    |  |                                    |   |  |                                            |    |  |                                   |   |  |                                           |  
|Income from operations                              |  | 5.9                                |   |  | 5.7                                        |    |  | 5.4                               |   |  | 6.8                                       |  
|                                                    |  |                                    |   | 
|Other income (expense):                             |  |                                    |   |  |                                            |    |  |                                   |   |  |                                           |  
|Interest expense, net                               |  | (3.2                               | ) |  | (1.9                                       | )  |  | (3.4                              | ) |  | (1.2                                      | )
|Loss on early extinguishment of debt                |  |                                   |   |  | (6.5                                       | )  |  |                                  |   |  | (2.3                                      | )
|                                                    |  |                                    |   |  |                                            |    |  |                                   |   |  |                                           |  
|Income (loss) before income taxes                   |  | 2.7                                |   |  | (2.7                                       | )  |  | 2.0                               |   |  | 3.3                                       |  
|Income tax (provision) benefit                      |  | (1.0                               | ) |  | 0.5                                        |    |  | (0.8                              | ) |  | (1.5                                      | )
|                                                    |  |                                    |   |  |                                            |    |  |                                   |   |  |                                           |  
|Net income (loss)                                   |  | 1.7                                | % |  | (2.2                                       | )% |  | 1.2                               | % |  | 1.8                                       | %
|                                                    |  |                                    |   |  |                                            |    |  |                                   |   |  |                                           |  



We provide medical oncology, cancer
center, and cancer research services to physician practices. We currently earn revenue from physician practices under comprehensive service agreements, under which we provide a comprehensive array of business services to affiliated practices and are
paid a service fee and reimbursed for all expenses, and under service line agreements through which we offer pharmaceutical purchasing and management services and cancer research services under separate agreements for each service line.



We derive revenue primarily in four areas:



 Comprehensive service fee revenues. Under our comprehensive service
agreements, we recognize revenues derived from amounts we bill and collect on behalf of affiliated practices, which are reduced by the amounts retained by those practices under our contracts. Service fee revenue is recorded when services are
rendered based on established or negotiated rates reduced by contractual adjustments, allowances for doubtful accounts and by the amounts retained by practices. Differences between estimated contractual adjustments and final settlements are reported
in the period when final settlements are determined.



-28-



---

##### Table of Contents

US ONCOLOGY, INC.

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF

OPERATIONS
continued



 Service line fees. In the medical oncology
services area under our service line agreements, we bill practices on a monthly basis for services rendered. These revenues include payment for all of the pharmaceutical agents used by the practice for which we pay the pharmaceutical manufacturers,
and a service fee for the pharmacy-related services we provide.



 GPO,
data and other pharmaceutical service fees. We receive fees from pharmaceutical companies for acting as a group purchasing organization (GPO) for our affiliated practices, as well as for providing informational and other services to
pharmaceutical companies. GPO fees are typically based upon the volume of drugs purchased by the practices. Fees for other services include amounts paid for data we collect and compile, as well as fees for other informational services we provide to
pharmaceutical companies.



 Clinical research fees. We receive
fees for clinical research services from pharmaceutical and biotechnology companies. These fees are separately negotiated for each study and typically include a management fee, per patient accrual fees and fees for achieving various study
milestones.



A portion of our revenue under our comprehensive service
agreements and our service line arrangements with affiliated practices are derived from sales of pharmaceutical products and are reported as product revenues. Our remaining revenues are reported as service revenues. Physician practices that enter
into comprehensive service agreements with us receive a broad range of services and receive pharmaceutical products. These products and services represent multiple deliverables delivered under a single contract, with a single fee. We have analyzed
the component of the contract attributable to the provision of products (pharmaceuticals) and the component of the contract attributable to the provision of services and attributed fair value to each component.



We retain all amounts we collect in respect of practice receivables. On a monthly basis, we
calculate what portion of their revenues our affiliated practices are entitled to retain by subtracting our accrued fees and accrued practice expenses from accrued revenues. We pay practices this remainder in cash, which they use primarily for
physician compensation. These amounts we remit to physician groups are excluded from our revenue, because they are not part of our fees. By paying physicians on a cash basis for accrued amounts, we finance their working capital.



The following table reflects our revenue by segment for the three and nine months ended
September 30, 2005 and the three and nine months ended September 30, 2004 (in thousands):



|                          |  |                                    |         |                                            |   |                                   |  |                                           |           |  |   |          
|------------------------- |  | ---------------------------------- | ------- | ------------------------------------------ | - | --------------------------------- |  | ----------------------------------------- | --------- |  | - | ---------
|                          |  | Three MonthsEndedSeptember 30,2005 |         | CombinedThree MonthsEndedSeptember 30,2004 |   | Nine MonthsEndedSeptember 30,2005 |  | CombinedNine MonthsEndedSeptember 30,2004
|Medical oncology services |  | $                                  | 563,228 |                                            | $ | 513,315                           |  | $                                         | 1,600,746 |  | $ | 1,453,154
|Cancer center services    |  |                                    | 72,879  |                                            |   | 63,420                            |  |                                           | 217,753   |  |   | 187,474  
|Other services            |  |                                    | 12,238  |                                            |   | 11,996                            |  |                                           | 35,111    |  |   | 38,342   
|                          |  |                                    |         |                                            |   |                                   |  |                                           |           |  |   |          
|                          |  | $                                  | 648,345 |                                            | $ | 588,731                           |  | $                                         | 1,853,610 |  | $ | 1,678,970
|                          |  |                                    |         |                                            |   |                                   |  |                                           |           |  |   |          



Governmental programs, such as
Medicare and Medicaid, are collectively the practices largest payors. For the three months ended September 30, 2005 and 2004, the affiliated practices derived 38.0% and 42.1%, respectively, of their net patient revenue from services
provided under the Medicare program (of which 2.2% and 3.5%, respectively, represents Medicare managed care) and 2.9% and 2.6%, respectively, of their net patient revenue from services provided under the state Medicaid programs. Capitation revenues
were less than 1% of total net patient revenue for both periods. Changes in the payor reimbursement rates, particularly Medicare and Medicaid, or affiliated practices payor mix can materially and adversely affect our revenues.



Revenues. Revenues for the quarter ended September 30, 2005 were
$648.3 million compared to $588.7 million for the quarter ended September 30, 2004, an increase of $59.6 million or 10.1%. Revenues for the nine months ended September 30, 2005 were $1,853.6 million compared to
$1,679.0 million for the nine months ended September 30, 2004, an increase of $174.6 million or 10.4%.



-29-



---

##### Table of Contents

US ONCOLOGY, INC.

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF

OPERATIONS
continued



Medical oncology revenues for the quarter ended
September 30, 2005 were $563.2 million, an increase of $49.9 million, or 9.7%, compared to the third quarter of 2004. Medical oncology revenues for the nine months ended September 30, 2005 were $1,600.7 million, an increase of $147.6
million, or 10.2%, compared to the nine months ended September 30, 2004. The increases are due to growth in pharmaceutical revenue attributed to physicians affiliated with the network during each of these periods. The number of medical
oncologists/hematologists affiliated with the Company increased to 805 at September 30, 2005 from 782 at September 30, 2004.



Cancer center revenues for the quarter ended September 30, 2005 were $72.9 million, an increase of $9.5 million, or 14.9%, compared to the third quarter of 2004.
Cancer center revenues for the nine months ended September 30, 2005 were $217.8 million, an increase of $30.3 million, or 16.2%, compared to the nine months ended September 30, 2004. The increases are due to the net addition of 7 radiation
oncology facilities and 13 radiation oncologists since September 30, 2004.



Cost of Products. Cost of products for the quarter ended September 30, 2005 increased to $400.9 million from $345.0 million in the third quarter of 2004. As a percentage of total revenue, cost of products was 61.8% during the
third quarter of 2005 and 58.6% for the third quarter of 2004. Cost of products for the nine months ended September 30, 2005 increased to $1,129.6 million or 14.7%, from $984.5 million in the nine months ended September 30, 2004. As a
percentage of total revenue, cost of products was 60.9% during the first nine months of 2005, compared to 58.6% for the nine months ended September 30, 2004. The reduction in margin on product revenues is primarily attributable to reduced
Medicare reimbursement rates as a result of the adoption of ASP pricing by Medicare, effective January 1, 2005.



Operating Compensation and Benefits. Operating compensation and benefits includes salaries and wages of our operating-level employees and the employees of our
affiliated practices (other than physicians). Operating compensation and benefits increased by $9.2 million, or 9.4%, to $107.1 million during the three months ended September 30, 2005 and by $23.4 million, or 8.1%, to $310.4 million during the
nine months ended September 30, 2005 over the comparable periods in the prior year. As a percentage of revenue, operating compensation and benefits were 16.6 % during the three month periods ended September 30, 2005 and
September 30, 2004 and 16.7% and 17.1% during the nine month periods ended September 30, 2005 and 2004, respectively.



Other Operating Costs. Other operating costs consist of rent, utilities, repairs and maintenance, insurance and other direct field costs. Other operating costs
increased by $5.4 million, or 9.4%, to $63.1 million during the three months ended September 30, 2005 and by $13.5 million, or 7.9%, to $183.1 million during the nine months ended September 30, 2005 over the comparable periods in the prior
year.



General and Administrative. General and administrative expenses
were $18.3 million in the third quarter of 2005 and $18.9 million in the third quarter of 2004, a decrease of $(0.6) million, or 3.2%. General and administrative expenses increased by $4.7 million, or 9.8%, to $52.9 million for the nine months ended
September 30, 2005 primarily due to investments in infrastructure to support development activities and increases in operational support to assist in the transition to ASP, combined with restricted stock amortization expense.



EBITDA.Overall, we experienced an improvement in operating margins associated with
earnings before taxes, interest, depreciation, amortization (including amortization of stock compensation). EBITDA was $165.9 million, or 9.0% of revenue, for the nine months ended September 30, 2005 compared to $135.2 or 8.1% of revenue, for
the same period in 2004. The improvement is attributable primarily to $16.1 million of merger-related charges and a $38.3 million loss on early extinguishment of debt associated with the August Transactions incurred in the nine months ended
September 30, 2004. Partially offsetting these costs, that did not recur in 2005, is the impact of lower oncology pharmaceutical reimbursement rates and the payment of $14.5 million to participants in our long-term cash incentive plan during
the nine month period ended September 30, 2005 as a result of the special dividend paid in connection with the issuance of $250.0 million notes by Holdings.



-30-



---

##### Table of Contents

US ONCOLOGY, INC.

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF

OPERATIONS
continued



The following table reconciles net income as shown in the
Condensed Consolidated Statement of Operations and Comprehensive Income to EBITDA and reconciles EBITDA to net cash provided by operating activities as shown in the Condensed Consolidated Statement of Cash Flows (in thousands):



|                                          |  |                                    |         |   |                                            |   |         |                                   |  |   |                                           |   |  |   |         |  
|----------------------------------------- |  | ---------------------------------- | ------- | - | ------------------------------------------ | - | ------- | --------------------------------- |  | - | ----------------------------------------- | - |  | - | ------- | -
|                                          |  | Three MonthsEndedSeptember 30,2005 |         |   | CombinedThree MonthsEndedSeptember 30,2004 |   |         | Nine MonthsEndedSeptember 30,2005 |  |   | CombinedNine MonthsEndedSeptember 30,2004 |  
|Net income (loss)                         |  | $                                  | 10,563  |   |                                            | $ | (13,616 | )                                 |  | $ | 22,749                                    |   |  | $ | 31,051  |  
|Interest expense, net and other income    |  |                                    | 20,833  |   |                                            |   | 11,077  |                                   |  |   | 62,166                                    |   |  |   | 19,378  |  
|Income taxes                              |  |                                    | 6,657   |   |                                            |   | (2,677  | )                                 |  |   | 14,976                                    |   |  |   | 25,285  |  
|Depreciation and amortization             |  |                                    | 20,942  |   |                                            |   | 20,202  |                                   |  |   | 63,132                                    |   |  |   | 59,492  |  
|Amortization of stock compensation        |  |                                    | 949     |   |                                            |   |        |                                   |  |   | 2,862                                     |   |  |   |        |  
|                                          |  |                                    |         |   |                                            |   |         |                                   |  |   |                                           |   |  |   |         |  
|EBITDA                                    |  |                                    | 59,944  |   |                                            |   | 14,986  |                                   |  |   | 165,885                                   |   |  |   | 135,206 |  
|Merger-related charges                    |  |                                    |        |   |                                            |   | 16,050  |                                   |  |   |                                          |   |  |   | 16,050  |  
|Loss on early extinguishment of debt      |  |                                    |        |   |                                            |   | 38,272  |                                   |  |   |                                          |   |  |   | 38,272  |  
|Changes in assets and liabilities         |  |                                    | (19,457 | ) |                                            |   | (8,804  | )                                 |  |   | (4,578                                    | ) |  |   | 33,113  |  
|Undistributed earnings in joint ventures  |  |                                    | 149     |   |                                            |   | 38      |                                   |  |   | 1,047                                     |   |  |   | 70      |  
|Deferred income taxes                     |  |                                    | 6,657   |   |                                            |   | 8,727   |                                   |  |   | 14,976                                    |   |  |   | 12,927  |  
|Interest expense, net and other income    |  |                                    | (20,833 | ) |                                            |   | (11,077 | )                                 |  |   | (62,166                                   | ) |  |   | (19,378 | )
|Income tax expense                        |  |                                    | (6,657  | ) |                                            |   | 2,677   |                                   |  |   | (14,976                                   | ) |  |   | (25,285 | )
|                                          |  |                                    |         |   |                                            |   |         |                                   |  |   |                                           |   |  |   |         |  
|Net cash provided by operating activities |  | $                                  | 19,803  |   |                                            | $ | 60,869  |                                   |  | $ | 100,188                                   |   |  | $ | 190,975 |  
|                                          |  |                                    |         |   |                                            |   |         |                                   |  |   |                                           |   |  |   |         |  



-31-



---

##### Table of Contents

US ONCOLOGY, INC.

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF

OPERATIONS
continued



Following is the EBITDA of our operating segments for the three
and nine months ended September 30, 2005 and the three and nine months ended September 30, 2004 (in thousands):



|                                                    |  |                                                |            |   |                      |   |          |       |  |   |                |   |  |       |         |   |  |   |            |  
|--------------------------------------------------- |  | ---------------------------------------------- | ---------- | - | -------------------- | - | -------- | ----- |  | - | -------------- | - |  | ----- | ------- | - |  | - | ---------- | -
|                                                    |  | Three Months Ended September 30, 2005          |           
|                                                    |  | MedicalOncologyServices                        |            |   | CancerCenterServices |   |          | Other |  |   | CorporateCosts |   |  | Total |        
|Product revenues                                    |  | $                                              | 418,724    |   |                      | $ |         |       |  | $ |               |   |  | $     |        |   |  | $ | 418,724    |  
|Service revenues                                    |  |                                                | 144,504    |   |                      |   | 72,879   |       |  |   | 12,238         |   |  |       |        |   |  |   | 229,621    |  
|                                                    |  |                                                |            |   |                      |   |          |       |  |   |                |   |  |       |         |   |  |   |            |  
|Total revenues                                      |  |                                                | 563,228    |   |                      |   | 72,879   |       |  |   | 12,238         |   |  |       |        |   |  |   | 648,345    |  
|Operating expenses                                  |  |                                                | (511,327   | ) |                      |   | (58,570  | )     |  |   | (12,415        | ) |  |       | (27,980 | ) |  |   | (610,292   | )
|                                                    |  |                                                |            |   |                      |   |          |       |  |   |                |   |  |       |         |   |  |   |            |  
|Income (loss) from operations                       |  |                                                | 51,901     |   |                      |   | 14,309   |       |  |   | (177           | ) |  |       | (27,980 | ) |  |   | 38,053     |  
|Add back: Depreciation and amortization             |  |                                                | 437        |   |                      |   | 10,446   |       |  |   | 347            |   |  |       | 9,712   |   |  |   | 20,942     |  
|Amortization of stock compensation                  |  |                                                |           |   |                      |   |         |       |  |   |               |   |  |       | 949     |   |  |   | 949        |  
|                                                    |  |                                                |            |   |                      |   |          |       |  |   |                |   |  |       |         |   |  |   |            |  
|EBITDA                                              |  | $                                              | 52,338     |   |                      | $ | 24,755   |       |  | $ | 170            |   |  | $     | (17,319 | ) |  | $ | 59,944     |  
|                                                    |  |                                                |            |   |                      |   |          |       |  |   |                |   |  |       |         |   |  |   |            |  
|                                                    | 
|                                                    |  | Combined Three Months Ended September 30, 2004 |           
|                                                    |  | MedicalOncologyServices                        |            |   | CancerCenterServices |   |          | Other |  |   | CorporateCosts |   |  | Total |        
|Product revenues                                    |  | $                                              | 362,958    |   |                      | $ |         |       |  | $ |               |   |  | $     |        |   |  | $ | 362,958    |  
|Service revenues                                    |  |                                                | 150,357    |   |                      |   | 63,420   |       |  |   | 11,996         |   |  |       |        |   |  |   | 225,773    |  
|                                                    |  |                                                |            |   |                      |   |          |       |  |   |                |   |  |       |         |   |  |   |            |  
|Total revenues                                      |  |                                                | 513,315    |   |                      |   | 63,420   |       |  |   | 11,996         |   |  |       |        |   |  |   | 588,731    |  
|Operating expenses                                  |  |                                                | (446,780   | ) |                      |   | (50,695  | )     |  |   | (11,648        | ) |  |       | (46,552 | ) |  |   | (555,675   | )
|                                                    |  |                                                |            |   |                      |   |          |       |  |   |                |   |  |       |         |   |  |   |            |  
|Income (loss) from operations                       |  |                                                | 66,535     |   |                      |   | 12,725   |       |  |   | 348            |   |  |       | (46,552 | ) |  |   | 33,056     |  
|Loss on early extinguishment of debt                |  |                                                |           |   |                      |   |         |       |  |   |               |   |  |       | (38,272 | ) |  |   | (38,272    | )
|Add back: Depreciation and amortization             |  |                                                | 21         |   |                      |   | 8,644    |       |  |   | 257            |   |  |       | 11,280  |   |  |   | 20,202     |  
|                                                    |  |                                                |            |   |                      |   |          |       |  |   |                |   |  |       |         |   |  |   |            |  
|EBITDA                                              |  | $                                              | 66,556     |   |                      | $ | 21,369   |       |  | $ | 605            |   |  | $     | (73,544 | ) |  | $ | 14,986     |  
|                                                    |  |                                                |            |   |                      |   |          |       |  |   |                |   |  |       |         |   |  |   |            |  
|                                                    | 
|                                                    |  | Nine Months Ended September 30, 2005           |           
|                                                    |  | MedicalOncologyServices                        |            |   | CancerCenterServices |   |          | Other |  |   | CorporateCosts |   |  | Total |        
|Product revenues                                    |  | $                                              | 1,181,431  |   |                      | $ |         |       |  | $ |               |   |  | $     |        |   |  | $ | 1,181,431  |  
|Service revenues                                    |  |                                                | 419,315    |   |                      |   | 217,753  |       |  |   | 35,111         |   |  |       |        |   |  |   | 672,179    |  
|                                                    |  |                                                |            |   |                      |   |          |       |  |   |                |   |  |       |         |   |  |   |            |  
|Total revenues                                      |  |                                                | 1,600,746  |   |                      |   | 217,753  |       |  |   | 35,111         |   |  |       |        |   |  |   | 1,853,610  |  
|Operating expenses                                  |  |                                                | (1,444,730 | ) |                      |   | (170,582 | )     |  |   | (38,472        | ) |  |       | (85,428 | ) |  |   | (1,739,212 | )
|Compensation expense under long-term incentive plan |  |                                                |           |   |                      |   |         |       |  |   |               |   |  |       | (14,507 | ) |  |   | (14,507    | )
|                                                    |  |                                                |            |   |                      |   |          |       |  |   |                |   |  |       |         |   |  |   |            |  
|Income (loss) from operations                       |  |                                                | 156,016    |   |                      |   | 47,171   |       |  |   | (3,361         | ) |  |       | (99,935 | ) |  |   | 99,891     |  
|Add back: Depreciation and amortization             |  |                                                | 474        |   |                      |   | 29,781   |       |  |   | 1,064          |   |  |       | 31,813  |   |  |   | 63,132     |  
|Amortization of stock compensation                  |  |                                                |           |   |                      |   |         |       |  |   |               |   |  |       | 2,862   |   |  |   | 2,862      |  
|                                                    |  |                                                |            |   |                      |   |          |       |  |   |                |   |  |       |         |   |  |   |            |  
|EBITDA                                              |  | $                                              | 156,490    |   |                      | $ | 76,952   |       |  | $ | (2,297         | ) |  | $     | (65,260 | ) |  | $ | 165,885    |  
|                                                    |  |                                                |            |   |                      |   |          |       |  |   |                |   |  |       |         |   |  |   |            |  



-32-



---

##### Table of Contents

US ONCOLOGY, INC.

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF

OPERATIONS
continued



|                                        |  |                                               |            |   |                      |   |          |       |  |   |                |   |  |       |          |   |  |   |            |  
|--------------------------------------- |  | --------------------------------------------- | ---------- | - | -------------------- | - | -------- | ----- |  | - | -------------- | - |  | ----- | -------- | - |  | - | ---------- | -
|                                        |  | Combined Nine Months Ended September 30, 2004 |           
|                                        |  | MedicalOncologyServices                       |            |   | CancerCenterServices |   |          | Other |  |   | CorporateCosts |   |  | Total |         
|Product revenues                        |  | $                                             | 1,050,887  |   |                      | $ |         |       |  | $ |               |   |  | $     |         |   |  | $ | 1,050,887  |  
|Service revenues                        |  |                                               | 402,267    |   |                      |   | 187,474  |       |  |   | 38,342         |   |  |       |         |   |  |   | 628,083    |  
|                                        |  |                                               |            |   |                      |   |          |       |  |   |                |   |  |       |          |   |  |   |            |  
|Total revenues                          |  |                                               | 1,453,154  |   |                      |   | 187,474  |       |  |   | 38,342         |   |  |       |         |   |  |   | 1,678,970  |  
|Operating expenses                      |  |                                               | (1,281,770 | ) |                      |   | (149,475 | )     |  |   | (35,261        | ) |  |       | (98,478  | ) |  |   | (1,564,984 | )
|                                        |  |                                               |            |   |                      |   |          |       |  |   |                |   |  |       |          |   |  |   |            |  
|Income (loss) from operations           |  |                                               | 171,384    |   |                      |   | 37,999   |       |  |   | 3,081          |   |  |       | (98,478  | ) |  |   | 113,986    |  
|Loss on early extinguishment of debt    |  |                                               |           |   |                      |   |         |       |  |   |               |   |  |       | (38,272  | ) |  |   | (38,272    | )
|Add back: Depreciation and amortization |  |                                               | 52         |   |                      |   | 25,512   |       |  |   | 751            |   |  |       | 33,177   |   |  |   | 59,492     |  
|                                        |  |                                               |            |   |                      |   |          |       |  |   |                |   |  |       |          |   |  |   |            |  
|EBITDA                                  |  | $                                             | 171,436    |   |                      | $ | 63,511   |       |  | $ | 3,832          |   |  | $     | (103,573 | ) |  | $ | 135,206    |  
|                                        |  |                                               |            |   |                      |   |          |       |  |   |                |   |  |       |          |   |  |   |            |  



Medical oncology services EBITDA
decreased to $52.3 million, or 9.3% of segment revenue, in the third quarter of 2005 from $66.6 million, or 13.0% of segment revenue, in the third quarter of 2004. This decrease is the result of the implementation of Medicare reimbursement changes,
partially offset by growth in pharmaceutical revenues attributed to physicians affiliated with the network in each of these periods.



Cancer center services EBITDA increased to $24.8 million during the third quarter of 2005 from $21.4 million during the same period in 2004. Cancer center EBITDA margin,
as a percent of cancer center revenue, remained relatively constant at 34.0% for both the third quarter of 2005 and 2004. The increase in EBITDA is attributable to the net addition of 7 radiation oncology facilities and 13 radiation oncologists
since the third quarter of 2004. Expansion of our cancer center network, increased demand for services and more efficient utilization of existing cancer center assets also contributed to the increase in the average number of radiation treatments and
diagnostic radiology scans per operating day over the third quarter of 2004.



Interest.Interest expense, net, increased to $20.8 million in the third quarter of 2005 from $11.1 million in the third quarter of 2004, an increase of $9.7 million. Interest expense, net increased by $42.2 million, to $62.2 million
during the nine months ended September 30, 2005 over the comparable periods in the prior year. These increases are attributable to additional indebtedness as a result of the August Transactions. As a percentage of revenue, interest expense,
net, increased to 3.2% for the third quarter of 2005 from 1.9% for the third quarter of 2004.



Income Taxes. Our effective tax rate was 39.7% for the nine months ended September 30, 2005 and 44.9% for the nine months ended September 30, 2004. The decrease in the effective tax rate is
attributable to non-deductible costs incurred in connection with the August Transactions during the third quarter of 2004.



Net Income.Net income increased $24.2 million to $10.6 million in the third quarter of 2005 from net loss of $13.6 million in the third quarter of 2004. The
increase is primarily attributable to the absence of $16.1 million merger-related charges and a $38.3 million loss on early extinguishment of debt associated with the August Transactions incurred during the third quarter of 2004. The increase is
partially offset by the impact of ASP-based reimbursement effective in 2005, $9.7 million incremental interest expense for indebtedness related to August Transactions and a higher income tax provision in the third quarter of 2005. Net income for the
nine months ended September 30, 2005 decreased by $8.3 million, or 26.8%, to $22.7 million over the comparable period in the prior year. The decrease is primarily attributable to the impact of ASP-based reimbursement effective in 2005, $42.2
million incremental interest expense for indebtedness related to August Transactions and $14.5 million incentive compensation incurred in the first quarter of 2005 as a result of a dividend paid to shareholders of our parent company, and is offset
by the absence of $16.1 million merger-related charges and a $38.3 million loss on early extinguishment of debt associated with the August Transactions incurred during the third quarter of 2004.



-33-



---

##### Table of Contents

US ONCOLOGY, INC.

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF

OPERATIONS
continued



Liquidity and Capital Resources



As of September 30, 2005, we had net working capital of $210.0 million, including cash
and cash equivalents of $130.6 million. We had current liabilities of $484.2 million, including $10.4 million in current maturities of long-term debt. We also have $969.8 million of long-term indebtedness. During the nine months ended
September 30, 2005, we generated $100.2 million in operating cash flow, and used $64.6 million and $25.4 million, respectively, for investing and financing activities. As of November 2, 2005, we had cash and cash equivalents of
approximately $150.8 million.



Cash Flows from Operating Activities



During the nine months ended September 30, 2005, we generated $100.2
million in cash flows from operating activities as compared to $191.0 million in the comparable prior year period. The decrease in operating cash flow is primarily due a $42.2 million increase in interest expense attributable to debt issued in the
August Transactions and the collection of $48.1 million of pharmaceutical rebates in October, 2005 that, under 2004 payment terms, would have been received during the third quarter.



Cash Flows from Investing Activities



During the nine months ended September 30, 2005 and 2004, we used $64.6 million and $57.5 million for investing activities, respectively. The investments consisted
primarily of $62.8 million and $57.5 million in capital expenditures, including $40.8 million and $42.2 million relating to the development and construction of cancer centers, respectively. During the nine months ended September 30, 2005
capital expenditures for our distribution initiative amounted to $10.9 million. Maintenance capital expenditures were $11.1 million and $15.3 million during the nine months ended September 30, 2005 and 2004, respectively.



Cash Flows from Financing Activities



During the nine months ended September 30, 2005 and 2004, we used $25.4 million in cash
for financing activities. The use of cash during this period is primarily related to $16.9 million in repayments under our term loan facility and an $11.0 million dividend paid to our parent in September, 2005 for debt service requirements. During
the nine months ended September 30, 2004 we used $191.0 million in cash for financing activities related primarily to repayment of existing indebtedness and the purchase of common stock and outstanding options, net of proceeds from the term
loan, senior notes and senior subordinated notes and equity proceeds contributed by Holdings, in connection with the August Transactions.



Also, during the quarter ended March 31, 2005, Holdings, whose sole asset is its investment in US Oncology, Inc., issued $250.0 million of Senior Floating Rate
Notes, due 2015 (the Notes). The Notes are senior unsecured obligations of Holdings and bear interest at a floating rate, reset semi-annually, equal to 6-month LIBOR plus 5.25%. Simultaneously with the financing, Holdings entered into an
interest rate swap arrangement, effectively fixing the interest rate at 9.4% for a period of two years ending March 15, 2007. Because Holdings sole asset is its investment in US Oncology, we plan to provide funds sufficient to service the
indebtedness through the payment of dividends to Holdings.



We will finance the
payment of interest on the Holdings notes through payment of periodic dividends. During the period that the interest rate has been fixed, annual interest expense will amount to approximately $23.5 million and may be more or less than that amount
thereafter. The terms of our existing senior secured credit facility, as well as the indentures governing the senior notes and senior subordinated notes, and certain other agreements, restrict US Oncology and certain subsidiaries from making
payments or transferring assets to Holdings, including dividends, loans or other distributions. Such restrictions include prohibition of dividends in an event of default and limitations on the total amount of dividends paid to Holdings. In the event
these agreements, or other considerations, do not permit us to provide Holdings with sufficient distributions to fund interest and principal payments on the Holdings Notes when due, Holdings may default on its notes unless other sources of funding
are available. Amounts available under this restricted payments provision amounted to $79.0 million as of September 30, 2005.



-34-



---

##### Table of Contents

US ONCOLOGY, INC.

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF

OPERATIONS
continued



Anticipated Capital Requirements



We currently expect our principal uses of funds in the near future to be the following:



| |  |  | Investment in inventory, equipment and leasehold improvements for our specialty pharmacy distribution initiative.
| | - |  | -----------------------------------------------------------------------------------------------------------------



| |  |  | Purchase of real estate and medical equipment for the development of new cancer centers, as well as installation of upgraded and replacement medical equipment at existing centers.
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | Payments made for acquisition of assets and additional consideration, if any, in connection with new practice affiliations and acquisitions.
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | Funding of working capital, including advance purchases of pharmaceuticals for price-hedging purposes or to obtain certain rebates and discounts under contracts with volume-based
thresholds.
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | Investments in information systems, including systems related to new initiatives such as our electronic medical record product, iKnowMed, and our pharmacy distribution operations.
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | Debt service requirements on our outstanding indebtedness, including dividends to fund debt service requirements of our parent.
| | - |  | -------------------------------------------------------------------------------------------------------------------------------



| |  |  | The Company expects to utilize its remaining net operating loss carryforward for federal income tax purposes in 2005 and will become a cash taxpayer in 2006.
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------



For all of 2005, we anticipate spending $80 to $90 million for
the development of cancer centers, purchase of clinical equipment and investment in information systems. The Company anticipates its specialty pharmacy distribution initiative in 2005 will require an investment of $15 million in systems, consultants
and leasehold improvements. In addition, the Company anticipates an additional working capital investment of approximately $120 to $130 million primarily in receivables and pharmaceutical inventory to adequately stock and operate the distribution
warehouse. This working capital investment initially began during the third quarter of 2005 and is expected to grow to an optimized level by the end of the first quarter of 2006. We expect such additional investment to be an ongoing working capital
requirement subject to the identification and implementation of working capital improvement opportunities after reaching full operating levels.



We expect to fund our current capital needs with (a) cash flow generated from operations, (b) borrowings under the existing $160 million revolving credit
facility, (c) lease or purchase money financing for certain equipment purchases and (d) indebtedness to physicians in connection with new affiliations. Our success in implementing our capital expenditure plans and our new distribution
initiatives could be adversely impacted by poor operating performance, resulting in reduced cash flow from operations. In addition, to the extent that poor performance or other factors impact our compliance with financial and other covenants under
our revolving credit facility, our ability to borrow under that facility or to find other financing sources could be limited. Furthermore, capital at financing terms satisfactory to management may be limited, due to market conditions or operating
performance.



-35-



---

##### Table of Contents

US ONCOLOGY, INC.



ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS



In the normal course of business, our financial position is routinely subjected to a variety of risks. We regularly assess these risks and have established policies and business practices to protect against the
adverse effects of these and other potential exposures.



Among these risks is
the market risk associated with interest rate movements on outstanding debt. Any borrowings under the credit facility contain an element of market risk from changes in interest rates. As of September 30, 2005, we had no outstanding borrowings
under our revolving credit facility. Historically, at times we have managed this risk, in part, through the use of interest rate swaps. We do not enter into interest rate swaps or hold other derivative financial instruments for speculative purposes.
We were not obligated under any interest rate swap agreements during the nine months ended September 30, 2004.



During the nine months ended September 30, 2005, Holdings issued $250.0 million of senior floating rate notes, due 2015. The notes are senior unsecured obligations
of Holdings and bear interest at a floating rate, reset semi-annually, equal to 6-month LIBOR plus 5.25%. In connection with the financing, Holdings entered into an interest rate swap arrangement, effectively fixing the interest rate at 9.4% for a
period of two years. The swap agreement, which has a notional amount of $250.0 million, was designated as a cash flow hedge and qualifies for the shortcut method of accounting. The income statement effects of the swap agreement, along with the
carrying value of the debt, related transaction costs and interest expense, are included in the financial statements of Holdings. Because Holdings sole asset is its investment in US Oncology, US Oncology plans to provide the necessary funds to
service this debt obligation through the payment of dividends to Holdings.



For
purposes of specific risk analysis, we use sensitivity analysis to determine the impact that market risk exposures may have on us. The financial instruments included in the sensitivity analysis consist of all of our cash and equivalents, long-term
and short-term debt and all derivative financial instruments.



To perform
sensitivity analysis, we assess the risk of loss in fair values from the impact of hypothetical changes in interest rates on market sensitive instruments. The market values for interest rate risk are computed based on the present value of future
cash flows as impacted by the changes in the rates attributable to the market risk being measured. The discount rates used for the present value computations were selected based on market interest rates in effect at September 30, 2005. The
market values that result from these computations are compared with the market values of these financial instruments at September 30, 2005. The differences in this comparison are the hypothetical gains or losses associated with each type of
risk. A 1% increase or decrease in the levels of interest rates on term loans, with all other variables held constant, would result in a corresponding increase or decrease to our annual interest expense of approximately $3.8 million.



-36-



---

##### Table of Contents

US ONCOLOGY, INC.



ITEM 4. CONTROLS AND PROCEDURES



We carried
out an evaluation, under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant
to Exchange Act Rule 13a-15 as of the end of the period covered by this report. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective in timely
alerting them to material information relating to the Company (including its consolidated subsidiaries) required to be included in our periodic SEC filings.



There was no change in internal control over financial reporting that occurred during our last fiscal quarter that has materially affected, or is reasonably likely to
materially affect, our internal control over financial reporting.



Management
previously acknowledged its responsibility for internal controls and seeks to continue to improve those controls. In addition, in order to achieve compliance with Section 404 of the Sarbanes-Oxley Act of 2002 within the prescribed period, we
have, since 2003, been engaged in a process to document and evaluate our internal controls over financial reporting. In this regard, management has dedicated internal resources, engaged outside consultants and adopted a detailed project work plan to
(i) assess the adequacy of our internal control over financial reporting, (ii) take steps to improve control processes where appropriate, (iii) validate through testing that controls are functioning as documented and
(iv) implement a continuous reporting and improvement process for internal control over financial reporting. During the second quarter of 2004, we commenced testing of internal controls that we had previously documented as part of this process.
The Company will first be subject to all of the requirements of Section 404, including inclusion of managements report on internal control over financial reporting and the independent registered public accounting firms assessment of
such internal controls when it files its annual report on Form 10-K with respect to its fiscal year ending December 31, 2007.



-37-



---

##### Table of Contents

US ONCOLOGY, INC.



PART II  Other Information



ITEM 1. LEGAL PROCEEDINGS



The provision of medical services by our affiliated practices entails an inherent risk of professional liability claims. We do not control the practice of medicine by the clinical staff or their compliance with
regulatory and other requirements directly applicable to practices. In addition, because the practices purchase and prescribe pharmaceutical products, they face the risk of product liability claims. In addition, because of licensing requirements and
affiliated practices participation in governmental health care programs, we and affiliated practices are, form time to time, subject to governmental audits and investigations, as well as internally initiated audits, some of which may result in
refunds to governmental programs. Although we and our practices maintain insurance coverage, successful malpractice, regulatory or product liability claims asserted against us or one of the practices in excess of insurance coverage could have a
material adverse effect on us.



We have become aware that we and certain of our
subsidiaries and affiliated practices are the subject of qui tam lawsuits (commonly referred to as whistle-blower suits). The United States has determined not to intervene in any of the qui tam suits of which we are aware and all but one
of such suits has been dismissed. The individuals who filed the remaining claim of which we are aware may still pursue the litigation, although none of those individuals has indicated intent to do so. Because qui tam actions are filed under seal,
there is a possibility that we could be the subject of other qui tam actions of which we are unaware. We intend to continue to investigate and vigorously defend ourselves against any and all such claims, and we continue to believe that we conduct
our operations in compliance with law.



Qui tam suits are brought by private
individuals, and there is no minimum evidentiary or legal threshold for bringing such a suit. The Department of Justice is legally required to investigate the allegations in these suits. The subject matter of many such claims may relate both to our
alleged actions and alleged actions of an affiliated practice. Because the affiliated practices are separate legal entities not controlled by us, such claims necessarily involve a more complicated, higher cost defense, and may adversely impact the
relationship between us and the practices. If the individuals who file complaints and/or the United States were to prevail in these claims against us, and the magnitude of the alleged wrongdoing were determined to be significant, the resulting
judgment could have a material adverse financial and operational effect on us including potential limitations in future participation in governmental reimbursement programs. In addition, addressing complaints and government investigations requires
us to devote significant financial and other resources to the process, regardless of the ultimate outcome of the claims.



We and our network physicians are defendants in a number of lawsuits involving employment and other disputes and breach of contract claims. In addition, we are involved
from time to time in disputes with, and claims by, our affiliated practices against us. Although we believe the allegations are customary for the size and scope of our operations, adverse judgments, individually or in the aggregate, could have a
material adverse effect on us.



Specifically, we are involved in litigation
with one net revenue model practice made up of 35 physicians with which we are trying to negotiate a service agreement termination or conversion to the earnings model or service line model. We initiated arbitration proceedings pursuant to a
provision in that service agreement providing for contract reformation in certain events. The practice has countered with a lawsuit that alleges, among other things, that we have breached the service agreement and that our service agreement is
unenforceable as a matter of public policy due to alleged violations of health care laws. The practice is seeking unspecified damages and a termination of the contract. We believe that our service agreement is lawful and enforceable and that we are
operating in accordance with applicable law. We intend to defend this lawsuit vigorously.



We believe the allegations in suits against us are customary for the size and scope of our operations. However, adverse judgments, individually or in the aggregate, could have a material adverse effect on us.



ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS



On July 15, 2005, the sole stockholder of US Oncology, Inc. (US
Oncology) elected James E. Dalton, Jr. to US Oncologys Board of Directors by unanimous written consent. Mr. Dalton has been appointed to serve on the Boards audit committee. Mr. Dalton previously served as a director of US Oncology
from 1998 until August 2004.



-38-



---

##### Table of Contents

US ONCOLOGY, INC.



ITEM 6. EXHIBITS



|(a) | Exhibits
|--- | --------



|              |  |                                                                                                                                                                                                                                                                                                                     
|------------- |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|ExhibitNumber |  | Description                                                                                                                                                                                                                                                                                                         
|2.1           |  | Agreement and Plan of Merger, dated as of March 20, 2004, among Oiler Holding Company, Oiler Acquisition Corp. and US Oncology, Inc. (filed as exhibit 2.1 to the Companys Form 8-K dated
March 20, 2004 and incorporated herein by reference.)                                                                    
|              | 
|3.1           |  | Amended and Restated Certificate of Incorporation (filed as Exhibit 3.1 to the Companys Registration Statement on Form S-4 filed December 17, 2004 and incorporated herein by
reference.)                                                                                                                          
|              | 
|3.2           |  | Amended and Restated By-Laws (filed as Exhibit 3.2 to the Companys Form 10-K filed March 21, 2003 and incorporated herein by reference.)                                                                                                                                                                           
|              | 
|4.1           |  | Indenture, dated as of February 1, 2002, among US Oncology, Inc., the Guarantors named therein and JP Morgan Chase Bank as Trustee (filed as Exhibit 3 to, and incorporated by reference from,
the Companys Form 8-K filed February 5, 2002.)                                                                      
|              | 
|4.2           |  | Form of 95/8% Senior Subordinated Note due 2012 (included
in Exhibit 4.1).                                                                                                                                                                                                                                          
|              | 
|4.3           |  | First Supplemental Indenture, dated as of August 20, 2004, among US Oncology, Inc., the Guarantors named therein and JP Morgan Chase Bank as Trustee. (filed as Exhibit 4.3 to the
Companys Registration Statement on Form S-4 filed December 17, 2004, and incorporated herein by reference.)                     
|              | 
|4.4           |  | Indenture, dated as of August 20, 2004, among Oiler Acquisition Corp. and LaSalle Bank National Association, as Trustee. (filed as Exhibit 4.4 to the Companys Registration Statement on
Form S-4 filed December 17, 2004, and incorporated herein by reference.)                                                  
|              | 
|4.5           |  | Form of 9% Senior Note due 2012 (included in Exhibit 4.4).                                                                                                                                                                                                                                                          
|              | 
|4.6           |  | First Supplemental Indenture, dated as of August 20, 2004, among US Oncology, Inc., the Guarantors named therein and LaSalle Bank National Association, as Trustee. (filed as Exhibit 4.6 to
the Companys Registration Statement on Form S-4 filed December 17, 2004, and incorporated herein by reference.)       
|              | 
|4.7           |  | Indenture, dated as of August 20, 2004, among Oiler Acquisition Corp. and LaSalle Bank National Association, as Trustee. (filed as Exhibit 4.7 to the Companys Registration Statement on
Form S-4 filed December 17, 2004, and incorporated herein by reference.)                                                  
|              | 
|4.8           |  | Form of 103/4% Senior Note due 2014 (included in Exhibit
4.7).                                                                                                                                                                                                                                                      
|              | 
|4.9           |  | First Supplemental Indenture, dated as of August 20, 2004, among US Oncology, Inc., the Guarantors named therein and LaSalle Bank National Association, as Trustee. (filed as Exhibit 4.9 to
the Companys Registration Statement on Form S-4 filed December 17, 2004, and incorporated herein by reference.)       
|              | 
|4.10          |  | Registration Rights Agreement, dated as of August 4, 2004, among Oiler Acquisition Corp. and Citigroup Global Markets Inc., as representative for the Initial Purchasers. (filed as Exhibit
4.10 to the Companys Registration Statement on Form S-4 filed December 17, 2004, and incorporated herein by reference.)
|              | 
|4.11          |  | Accession Agreement, dated as of August 20, 2004, among the Guarantors listed therein. (filed as Exhibit 4.11 to the Companys Registration Statement on Form S-4 filed December 17, 2004,
and incorporated herein by reference.)                                                                                   
|              | 
|31.1          |  | Certification of Chief Executive Officer                                                                                                                                                                                                                                                                            
|              | 
|31.2          |  | Certification of Chief Financial Officer                                                                                                                                                                                                                                                                            
|              | 
|32.1          |  | Certification of Chief Executive Officer                                                                                                                                                                                                                                                                            
|              | 
|32.2          |  | Certification of Chief Financial Officer                                                                                                                                                                                                                                                                            



-39-



---

##### Table of Contents

|(b) | Reports on Form 8-K
|--- | -------------------



The Company filed an 8-K on July 21, 2005, disclosing under Item 5.02 the election of James E. Dalton, Jr. to US Oncologys Board of Directors.



The Company filed an 8-K on August 10, 2005, disclosing under Item 2.02 a company
press release regarding its results of operations for the quarter ended June 30, 2005.



-40-



---

##### Table of Contents

US ONCOLOGY, INC.



SIGNATURES



Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



US ONCOLOGY, INC.Date:November 14, 2005:



By:

/s/ Bruce D. BroussardBruce D. Broussard,President and Chief Financial Officer (duly authorized duly authorized signatory and principal financial officer)Date:November 14, 2005:



By:

/s/ Vicki H. HitzhusenVicki H. Hitzhusen,Chief Accounting Officer(principal accounting officer)




-41-